BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995-2004. [PMID: 18923165 DOI: 10.1056/nejmoa0804525] [Cited by in Crossref: 886] [Cited by in F6Publishing: 473] [Article Influence: 68.2] [Reference Citation Analysis]
Number Citing Articles
1 Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010;61:317-28. [PMID: 20059340 DOI: 10.1146/annurev.med.080608.100623] [Cited by in Crossref: 160] [Cited by in F6Publishing: 145] [Article Influence: 14.5] [Reference Citation Analysis]
2 Jin J, Zhu P, Liao Y, Li J, Liao W, He S. Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection. Oncotarget 2015;6:19217-27. [PMID: 26057470 DOI: 10.18632/oncotarget.4265] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
3 Chew V, Toh HC, Abastado JP. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol 2012;2012:608406. [PMID: 22927846 DOI: 10.1155/2012/608406] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 8.1] [Reference Citation Analysis]
4 Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS. Biomarkers for the Early Detection of Hepatocellular Carcinoma.Cancer Epidemiol Biomarkers Prev. 2020;29:2495-2503. [PMID: 32238405 DOI: 10.1158/1055-9965.EPI-20-0005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
5 Hu J, Wang Z, Fan J, Dai Z, He YF, Qiu SJ, Huang XW, Sun J, Xiao YS, Song K, Shi YH, Sun QM, Yang XR, Shi GM, Yu L, Yang GH, Ding ZB, Gao Q, Tang ZY, Zhou J. Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation. PLoS One 2011;6:e26003. [PMID: 21998744 DOI: 10.1371/journal.pone.0026003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
6 Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res 2015;4:256-69. [PMID: 26213686 DOI: 10.3978/j.issn.2218-676X.2015.06.04] [Cited by in F6Publishing: 112] [Reference Citation Analysis]
7 Beck AH, Weng Z, Witten DM, Zhu S, Foley JW, Lacroute P, Smith CL, Tibshirani R, van de Rijn M, Sidow A, West RB. 3'-end sequencing for expression quantification (3SEQ) from archival tumor samples. PLoS One 2010;5:e8768. [PMID: 20098735 DOI: 10.1371/journal.pone.0008768] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 9.2] [Reference Citation Analysis]
8 Yue X, Zhang Z, Liang X, Gao L, Zhang X, Zhao D, Liu X, Ma H, Guo M, Spear BT, Gong Y, Ma C. Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclins A and E. Gastroenterology 2012;142:1559-70.e2. [PMID: 22406477 DOI: 10.1053/j.gastro.2012.02.049] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
9 Parry RM, Jones W, Stokes TH, Phan JH, Moffitt RA, Fang H, Shi L, Oberthuer A, Fischer M, Tong W, Wang MD. k-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction. Pharmacogenomics J 2010;10:292-309. [PMID: 20676068 DOI: 10.1038/tpj.2010.56] [Cited by in Crossref: 74] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
10 Berasain C, Elizalde M, Urtasun R, Castillo J, García-Irigoyen O, Uriarte I, Latasa MU, Prieto J, Avila MA. Alterations in the expression and activity of pre-mRNA splicing factors in hepatocarcinogenesis. Hepat Oncol 2014;1:241-52. [PMID: 30190958 DOI: 10.2217/hep.13.17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
11 Goossens N, Jornayvaz FR. Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease. Nutrients 2017;9:E1077. [PMID: 28956824 DOI: 10.3390/nu9101077] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
12 Wijetunga NA, Pascual M, Tozour J, Delahaye F, Alani M, Adeyeye M, Wolkoff AW, Verma A, Greally JM. A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets. Oncogene. 2017;36:2030-2044. [PMID: 27721404 DOI: 10.1038/onc.2016.340] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
13 Kocabayoglu P, Lade A, Lee YA, Dragomir AC, Sun X, Fiel MI, Thung S, Aloman C, Soriano P, Hoshida Y, Friedman SL. β-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis. J Hepatol 2015;63:141-7. [PMID: 25678385 DOI: 10.1016/j.jhep.2015.01.036] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 13.3] [Reference Citation Analysis]
14 Zhu GQ, Yang Y, Chen EB, Wang B, Xiao K, Shi SM, Zhou ZJ, Zhou SL, Wang Z, Shi YH, Fan J, Zhou J, Liu TS, Dai Z. Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. J Transl Med 2019;17:203. [PMID: 31215439 DOI: 10.1186/s12967-019-1946-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
15 Désert R, Nieto N, Musso O. Dimensions of hepatocellular carcinoma phenotypic diversity. World J Gastroenterol 2018;24:4536-47. [PMID: 30386103 DOI: 10.3748/wjg.v24.i40.4536] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
16 Davidsson S, Fiorentino M, Giunchi F, Eriksson M, Erlandsson A, Sundqvist P, Carlsson J. Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma. Eur Urol Open Sci 2020;20:62-71. [PMID: 34337459 DOI: 10.1016/j.euros.2020.06.003] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Guo B, Tan X, Cen H. EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma. PLoS One 2020;15:e0242191. [PMID: 33180829 DOI: 10.1371/journal.pone.0242191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Schadt EE, Woo S, Hao K. Bayesian method to predict individual SNP genotypes from gene expression data. Nat Genet 2012;44:603-8. [PMID: 22484626 DOI: 10.1038/ng.2248] [Cited by in Crossref: 90] [Cited by in F6Publishing: 60] [Article Influence: 10.0] [Reference Citation Analysis]
19 Wright JH, Johnson MM, Shimizu-Albergine M, Bauer RL, Hayes BJ, Surapisitchat J, Hudkins KL, Riehle KJ, Johnson SC, Yeh MM, Bammler TK, Beyer RP, Gilbertson DG, Alpers CE, Fausto N, Campbell JS. Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma. Int J Cancer. 2014;134:778-788. [PMID: 23929039 DOI: 10.1002/ijc.28421] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
20 Sun B, Karin M. Inflammation and liver tumorigenesis. Front Med. 2013;7:242-254. [PMID: 23681888 DOI: 10.1007/s11684-013-0256-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
21 Villanueva A, Luedde T. The transition from inflammation to cancer in the liver. Clin Liver Dis (Hoboken) 2016;8:89-93. [PMID: 31041071 DOI: 10.1002/cld.578] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
22 Ao L, Song X, Li X, Tong M, Guo Y, Li J, Li H, Cai H, Li M, Guan Q, Yan H, Guo Z. An individualized prognostic signature and multi‑omics distinction for early stage hepatocellular carcinoma patients with surgical resection. Oncotarget 2016;7:24097-110. [PMID: 27006471 DOI: 10.18632/oncotarget.8212] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
23 Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A, Bataller R, Lefkowitch JH, Bower M, Friedman R, Sartor RB, Rabadan R, Schwabe RF. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012;21:504-16. [PMID: 22516259 DOI: 10.1016/j.ccr.2012.02.007] [Cited by in Crossref: 637] [Cited by in F6Publishing: 578] [Article Influence: 70.8] [Reference Citation Analysis]
24 Chen VL, Xu D, Wicha MS, Lok AS, Parikh ND. Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review. Clin Gastroenterol Hepatol 2020; 18: 2879-2902. e9. [PMID: 32289533 DOI: 10.1016/j.cgh.2020.04.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
25 Lee JS, Kim JH, Park YY, Mills GB. Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat 2011;43:205-11. [PMID: 22247704 DOI: 10.4143/crt.2011.43.4.205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
26 Pinter M, Weinmann A, Wörns MA, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W. Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United European Gastroenterol J 2017;5:987-96. [PMID: 29163965 DOI: 10.1177/2050640617695698] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
27 Pemov A, Park C, Reilly KM, Stewart DR. Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency. BMC Genomics 2010;11:194. [PMID: 20307317 DOI: 10.1186/1471-2164-11-194] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
28 Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010;143:355-366. [PMID: 21029859 DOI: 10.1016/j.cell.2010.09.043] [Cited by in Crossref: 287] [Cited by in F6Publishing: 251] [Article Influence: 26.1] [Reference Citation Analysis]
29 Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol. 2015;21:105-114. [PMID: 26157746 DOI: 10.3350/cmh.2015.21.2.105] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 13.3] [Reference Citation Analysis]
30 Hyeon J, Ahn S, Lee JJ, Song DH, Park CK. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig Dis Sci. 2013;58:1916-1922. [PMID: 23456506 DOI: 10.1007/s10620-013-2609-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
31 Berasain C, Avila MA. Regulation of hepatocyte identity and quiescence. Cell Mol Life Sci 2015;72:3831-51. [DOI: 10.1007/s00018-015-1970-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
32 Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69:7385-7392. [PMID: 19723656 DOI: 10.1158/0008-5472.can-09-1089] [Cited by in Crossref: 619] [Cited by in F6Publishing: 372] [Article Influence: 51.6] [Reference Citation Analysis]
33 Duenwald S, Zhou M, Wang Y, Lejnine S, Kulkarni A, Graves J, Smith R, Castle J, Tokiwa G, Fine B, Dai H, Fare T, Marton M. Development of a microarray platform for FFPET profiling: application to the classification of human tumors. J Transl Med 2009;7:65. [PMID: 19638234 DOI: 10.1186/1479-5876-7-65] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
34 Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S, Shimizu K. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One. 2011;6:e16435. [PMID: 21298008 DOI: 10.1371/journal.pone.0016435] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 9.0] [Reference Citation Analysis]
35 Kudo A, Mogushi K, Takayama T, Matsumura S, Ban D, Irie T, Ochiai T, Nakamura N, Tanaka H, Anzai N, Sakamoto M, Tanaka S, Arii S. Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study. J Gastroenterol. 2014;49:502-510. [PMID: 23543312 DOI: 10.1007/s00535-013-0791-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
36 Nault JC. Next generation sequencing, inter-tumor heterogeneity and prognosis of hepatitis B related hepatocellular carcinoma. Chin J Cancer Res 2014;26:730-1. [PMID: 25561773 DOI: 10.3978/j.issn.1000-9604.2014.12.11] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Balachandran VP, Arora A, Gönen M, Ito H, Turcotte S, Shia J, Viale A, Snoeren N, van Hooff SR, Rinkes IH, Adam R, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI. A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases. Clin Cancer Res 2016;22:2575-82. [PMID: 26733613 DOI: 10.1158/1078-0432.CCR-15-1071] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
38 Zhang JB, Zhang B, Guo L, Lin ZH, Li XQ, Guo K, Sun HC, Ye QH. Peritumoral Cbl is a strong independent prognostic marker after curative resection of hepatocellular carcinoma. Oncotarget 2015;6:40223-34. [PMID: 26474280 DOI: 10.18632/oncotarget.5540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
39 Sojoodi M, Wei L, Erstad DJ, Yamada S, Fujii T, Hirschfield H, Kim RS, Lauwers GY, Lanuti M, Hoshida Y, Tanabe KK, Fuchs BC. Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma. Cancer Prev Res (Phila) 2020;13:497-508. [PMID: 32253266 DOI: 10.1158/1940-6207.CAPR-19-0383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
40 Woo HG, Park ES, Thorgeirsson SS, Kim YJ. Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog 2011;50:235-43. [PMID: 21465573 DOI: 10.1002/mc.20691] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
41 Wang L, Sun L, Huang J, Jiang M. Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation. Cell Prolif. 2011;44:291-299. [PMID: 21535270 DOI: 10.1111/j.1365-2184.2011.00752.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
42 Spano D, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, Tornillo L, Capasso M, Tiribelli C, Iolascon A. Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med 2010;16:102-15. [PMID: 20200618 DOI: 10.2119/molmed.2009.00119] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
43 Aufhauser DD Jr, Sadot E, Murken DR, Eddinger K, Hoteit M, Abt PL, Goldberg DS, DeMatteo RP, Levine MH. Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy. Ann Surg 2018;267:922-8. [PMID: 28085695 DOI: 10.1097/SLA.0000000000002135] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 10.5] [Reference Citation Analysis]
44 Shrestha R, Prithviraj P, Anaka M, Bridle KR, Crawford DHG, Dhungel B, Steel JC, Jayachandran A. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. Front Oncol. 2018;8:269. [PMID: 30057891 DOI: 10.3389/fonc.2018.00269] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 12.7] [Reference Citation Analysis]
45 Morise Z, Kawabe N, Tomishige H, Nagata H, Kawase J, Arakawa S, Yoshida R, Isetani M. Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol. 2014;20:14381-14392. [PMID: 25339825 DOI: 10.3748/wjg.v20.i39.14381] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
46 Tyekucheva S, Martin NE, Stack EC, Wei W, Vathipadiekal V, Waldron L, Fiorentino M, Lis RT, Stampfer MJ, Loda M, Parmigiani G, Mucci LA, Birrer M. Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. J Mol Diagn 2015;17:374-81. [PMID: 25937617 DOI: 10.1016/j.jmoldx.2015.02.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
47 Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest 2013;123:1911-8. [PMID: 23635789 DOI: 10.1172/JCI66024] [Cited by in Crossref: 310] [Cited by in F6Publishing: 211] [Article Influence: 38.8] [Reference Citation Analysis]
48 Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011;140:1501-12.e2. [PMID: 21320499 DOI: 10.1053/j.gastro.2011.02.006.] [Reference Citation Analysis]
49 Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009;41:843-848. [PMID: 19483683 DOI: 10.1038/ng.392] [Cited by in Crossref: 576] [Cited by in F6Publishing: 539] [Article Influence: 48.0] [Reference Citation Analysis]
50 Goossens N, Nakagawa S, Hoshida Y. Molecular prognostic prediction in liver cirrhosis. World J Gastroenterol 2015;21:10262-73. [PMID: 26420954 DOI: 10.3748/wjg.v21.i36.10262] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
51 Zhuang L, Wu Y, Han J, Ling X, Wang L, Zhu C, Fu Y. A network biology approach to discover the molecular biomarker associated with hepatocellular carcinoma. Biomed Res Int 2014;2014:278956. [PMID: 24949431 DOI: 10.1155/2014/278956] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
52 Pedica F, Ruzzenente A, Bagante F, Capelli P, Cataldo I, Pedron S, Iacono C, Chilosi M, Scarpa A, Brunelli M. A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse. PLoS One. 2013;8:e68203. [PMID: 23874541 DOI: 10.1371/journal.pone.0068203] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
53 Liao R, Du CY, Gong JP, Luo F. HBV-DNA Load-Related Peritumoral Inflammation and ALBI Scores Predict HBV Associated Hepatocellular Carcinoma Prognosis after Curative Resection. J Oncol 2018;2018:9289421. [PMID: 30327670 DOI: 10.1155/2018/9289421] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
54 Nakagawa S, Wei L, Song WM, Higashi T, Ghoshal S, Kim RS, Bian CB, Yamada S, Sun X, Venkatesh A, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, Ahmad NB, Hoshida H, Erstad DJ, Gunasekaran G, Lee Y, Yu ML, Chuang WL, Dai CY, Kobayashi M, Kumada H, Beppu T, Baba H, Mahajan M, Nair VD, Lanuti M, Villanueva A, Sangiovanni A, Iavarone M, Colombo M, Llovet JM, Subramanian A, Tager AM, Friedman SL, Baumert TF, Schwarz ME, Chung RT, Tanabe KK, Zhang B, Fuchs BC, Hoshida Y; Precision Liver Cancer Prevention Consortium. Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell 2016;30:879-90. [PMID: 27960085 DOI: 10.1016/j.ccell.2016.11.004] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 25.3] [Reference Citation Analysis]
55 Tang B, Tang F, Li B, Yuan S, Xu Q, Tomlinson S, Jin J, Hu W, He S. High USP22 expression indicates poor prognosis in hepatocellular carcinoma. Oncotarget 2015;6:12654-67. [PMID: 25909224 DOI: 10.18632/oncotarget.3705] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
56 Hyeon J, Ahn S, Lee JJ, Song DH, Park CK. Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma. Korean J Pathol 2013;47:130-6. [PMID: 23667372 DOI: 10.4132/KoreanJPathol.2013.47.2.130] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
57 Lin YJ, Ho CM. Is the Rationale of Anatomical Liver Resection for Hepatocellular Carcinoma Universally Adoptable? A Hypothesis-Driven Review. Medicina (Kaunas) 2021;57:131. [PMID: 33540784 DOI: 10.3390/medicina57020131] [Reference Citation Analysis]
58 Liao CC, Ward N, Marsh S, Arulampalam T, Norton JD. Mass spectrometry protein expression profiles in colorectal cancer tissue associated with clinico-pathological features of disease. BMC Cancer. 2010;10:410. [PMID: 20691062 DOI: 10.1186/1471-2407-10-410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
59 Tsuchiya M, Parker JS, Kono H, Matsuda M, Fujii H, Rusyn I. Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer. 2010;9:74. [PMID: 20380719 DOI: 10.1186/1476-4598-9-74] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
60 Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144:512-527. [PMID: 23313965 DOI: 10.1053/j.gastro.2013.01.002] [Cited by in Crossref: 395] [Cited by in F6Publishing: 356] [Article Influence: 49.4] [Reference Citation Analysis]
61 Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology. 2020;71:1247-1261. [PMID: 31378984 DOI: 10.1002/hep.30889] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 32.5] [Reference Citation Analysis]
62 Sheppard S, Ferry A, Guedes J, Guerra N. The Paradoxical Role of NKG2D in Cancer Immunity. Front Immunol 2018;9:1808. [PMID: 30150983 DOI: 10.3389/fimmu.2018.01808] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
63 Cao L, Cheng H, Jiang Q, Li H, Wu Z. APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma. Aging (Albany NY). 2020;12:4573-4591. [PMID: 32167932 DOI: 10.18632/aging.102913] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
64 Pancoska P, De Giorgio M, Fagiuoli S, Carr BI. Small HCCs identified by screening. Dig Dis Sci 2011;56:3078-85. [PMID: 21465143 DOI: 10.1007/s10620-011-1687-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
65 Zhuang PY, Zhang KW, Wang JD, Zhou XP, Liu YB, Quan ZW, Shen J. Effect of TALEN-mediated IL-6 knockout on cell proliferation, apoptosis, invasion and anti-cancer therapy in hepatocellular carcinoma (HCC-LM3) cells. Oncotarget 2017;8:77915-27. [PMID: 29100435 DOI: 10.18632/oncotarget.20946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
66 Hodgin JB, Borczuk AC, Nasr SH, Markowitz GS, Nair V, Martini S, Eichinger F, Vining C, Berthier CC, Kretzler M. A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am J Pathol. 2010;177:1674-1686. [PMID: 20847290 DOI: 10.2353/ajpath.2010.090746] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 6.9] [Reference Citation Analysis]
67 Liao W, Huang G, Liao Y, Yang J, Chen Q, Xiao S, Jin J, He S, Wang C. High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma. Oncotarget 2014;5:10271-9. [PMID: 25431949 DOI: 10.18632/oncotarget.2082] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
68 Liao W, Zhang J, Zhu Q, Qin L, Yao W, Lei B, Shi W, Yuan S, Tahir SA, Jin J, He S. Preoperative Neutrophil-to-Lymphocyte Ratio as a New Prognostic Marker in Hepatocellular Carcinoma after Curative Resection. Transl Oncol 2014;7:248-55. [PMID: 24704092 DOI: 10.1016/j.tranon.2014.02.011] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 6.4] [Reference Citation Analysis]
69 Morise Z, Kawabe N, Tomishige H, Nagata H, Kawase J, Arakawa S, Yoshida R, Isetani M. Recent advances in liver resection for hepatocellular carcinoma. Front Surg. 2014;1:21. [PMID: 25593945 DOI: 10.3389/fsurg.2014.00021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
70 Fountzilas E, Markou K, Vlachtsis K, Nikolaou A, Arapantoni-Dadioti P, Ntoula E, Tassopoulos G, Bobos M, Konstantinopoulos P, Fountzilas G, Spentzos D. Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer. Ann Oncol 2012;23:2146-53. [PMID: 22219018 DOI: 10.1093/annonc/mdr576] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
71 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
72 Utsunomiya T, Shimada M, Morine Y, Tajima A, Imoto I. Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis. Cancer Sci 2014;105:749-54. [PMID: 24766251 DOI: 10.1111/cas.12431] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
73 Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, Gouysse G, McKay-Chopin S, Tavtigian SV, Scoazec JY, Herceg Z. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One. 2010;5:e9749. [PMID: 20305825 DOI: 10.1371/journal.pone.0009749] [Cited by in Crossref: 142] [Cited by in F6Publishing: 129] [Article Influence: 12.9] [Reference Citation Analysis]
74 Budhu A, Ji J, Wang XW. The clinical potential of microRNAs. J Hematol Oncol 2010;3:37. [PMID: 20925959 DOI: 10.1186/1756-8722-3-37] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 6.9] [Reference Citation Analysis]
75 Wu TJ, Chang SS, Li CW, Hsu YH, Chen TC, Lee WC, Yeh CT, Hung MC. Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial-Mesenchymal Transition after Resection. Clin Cancer Res 2016;22:1800-12. [PMID: 26655845 DOI: 10.1158/1078-0432.CCR-15-0780] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
76 Ponziani FR, Nicoletti A, Gasbarrini A, Pompili M. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11:1758835919848184. [PMID: 31205505 DOI: 10.1177/1758835919848184] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
77 Rohr-Udilova N, Klinglmüller F, Schulte-Hermann R, Stift J, Herac M, Salzmann M, Finotello F, Timelthaler G, Oberhuber G, Pinter M, Reiberger T, Jensen-Jarolim E, Eferl R, Trauner M. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Sci Rep 2018;8:6220. [PMID: 29670256 DOI: 10.1038/s41598-018-24437-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 22.7] [Reference Citation Analysis]
78 Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. J Clin Med 2021;10:977. [PMID: 33801181 DOI: 10.3390/jcm10050977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
79 Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012;56:769-75. [PMID: 22378017 DOI: 10.1002/hep.25670] [Cited by in Crossref: 249] [Cited by in F6Publishing: 227] [Article Influence: 27.7] [Reference Citation Analysis]
80 Hicks DF, Goossens N, Blas-García A, Tsuchida T, Wooden B, Wallace MC, Nieto N, Lade A, Redhead B, Cederbaum AI, Dudley JT, Fuchs BC, Lee YA, Hoshida Y, Friedman SL. Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. Sci Rep 2017;7:42563. [PMID: 28256512 DOI: 10.1038/srep42563] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
81 Freedman JA, Augustine CK, Selim AM, Holshausen KC, Wei Z, Tsamis KA, Hsu DS, Dressman HK, Barry WT, Tyler DS, Nevins JR. A methodology for utilization of predictive genomic signatures in FFPE samples. BMC Med Genomics 2011;4:58. [PMID: 21745407 DOI: 10.1186/1755-8794-4-58] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
82 Pancoska P, Carr BI. Macro- and micro-environmental factors in clinical hepatocellular cancer. Semin Oncol 2014;41:185-94. [PMID: 24787292 DOI: 10.1053/j.seminoncol.2014.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
83 Shibahara J, Ando S, Hayashi A, Sakamoto Y, Hesegawa K, Kokudo N, Fukayama M. Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma. Springerplus 2014;3:721. [PMID: 26034695 DOI: 10.1186/2193-1801-3-721] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
84 Berasain C, Avila MA. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol. 2014;49:9-23. [PMID: 24318021 DOI: 10.1007/s00535-013-0907-x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 9.1] [Reference Citation Analysis]
85 Zahavi T, Lanton T, Divon MS, Salmon A, Peretz T, Galun E, Axelrod JH, Sonnenblick A. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. Oncotarget 2016;7:4860-70. [PMID: 26695439 DOI: 10.18632/oncotarget.6638] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
86 Wang XW, Thorgeirsson SS. Genome-based predictors for HCC outcomes: a matter of tumor and/or stroma. J Hepatol 2009;51:596-7. [PMID: 20625453 DOI: 10.1016/j.jhep.2009.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer 2015;121:2874-82. [PMID: 26079399 DOI: 10.1002/cncr.29528] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
88 Qian Y, Daza J, Itzel T, Betge J, Zhan T, Marmé F, Teufel A. Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. Cells 2021;10:648. [PMID: 33804045 DOI: 10.3390/cells10030648] [Reference Citation Analysis]
89 Hao K, Lamb J, Zhang C, Xie T, Wang K, Zhang B, Chudin E, Lee NP, Mao M, Zhong H, Greenawalt D, Ferguson MD, Ng IO, Sham PC, Poon RT, Molony C, Schadt EE, Dai H, Luk JM. Clinicopathologic and gene expression parameters predict liver cancer prognosis. BMC Cancer 2011;11:481. [PMID: 22070665 DOI: 10.1186/1471-2407-11-481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
90 Lamb JR, Zhang C, Xie T, Wang K, Zhang B, Hao K, Chudin E, Fraser HB, Millstein J, Ferguson M, Suver C, Ivanovska I, Scott M, Philippar U, Bansal D, Zhang Z, Burchard J, Smith R, Greenawalt D, Cleary M, Derry J, Loboda A, Watters J, Poon RT, Fan ST, Yeung C, Lee NP, Guinney J, Molony C, Emilsson V, Buser-Doepner C, Zhu J, Friend S, Mao M, Shaw PM, Dai H, Luk JM, Schadt EE. Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting. PLoS One 2011;6:e20090. [PMID: 21750698 DOI: 10.1371/journal.pone.0020090] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
91 Ozawa K, Tsumoto H, Wei W, Tang CH, Komatsubara AT, Kawafune H, Shimizu K, Liu L, Tsujimoto G. Proteomic analysis of the role of S-nitrosoglutathione reductase in lipopolysaccharide-challenged mice. Proteomics 2012;12:2024-35. [PMID: 22623366 DOI: 10.1002/pmic.201100666] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
92 Mueller JL, King LY, Johnson KB, Gao T, Nephew LD, Kothari D, Simpson MA, Zheng H, Wei L, Corey KE, Misdraji J, Lee JH, Lin MV, Gogela NA, Fuchs BC, Tanabe KK, Gordon FD, Curry MP, Chung RT. Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. Clin Transplant 2016;30:452-60. [PMID: 26854475 DOI: 10.1111/ctr.12710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
93 Siegel AB, Olsen SK, Magun A, Brown RS. Sorafenib: where do we go from here? Hepatology. 2010;52:360-369. [PMID: 20578152 DOI: 10.1002/hep.23633] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 6.1] [Reference Citation Analysis]
94 Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, Kim JH, Hwang JE, Jang HJ, Lee HS, Kim SC, Jeong W, Kim SS, Park ES, Heo J, Kim YJ, Kim DG, Leem SH, Kaseb A, Hassan MM, Cha M, Chu IS, Johnson RL, Park YY, Lee JS. Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma. Clin Cancer Res 2016;22:1256-64. [PMID: 26459179 DOI: 10.1158/1078-0432.CCR-15-1447] [Cited by in Crossref: 60] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
95 Ragina NP, Schlosser K, Knott JG, Senagore PK, Swiatek PJ, Chang EA, Fakhouri WD, Schutte BC, Kiupel M, Cibelli JB. Downregulation of H19 improves the differentiation potential of mouse parthenogenetic embryonic stem cells. Stem Cells Dev 2012;21:1134-44. [PMID: 21793658 DOI: 10.1089/scd.2011.0152] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
96 Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, Nsengimana J, Edward S, Sanders DS, Cook M, Powell B, Boon A, Elliott F, de Kort F, Knowles MA, Bishop DT, Newton-Bishop J. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 2009;15:6939-46. [PMID: 19887478 DOI: 10.1158/1078-0432.CCR-09-1631] [Cited by in Crossref: 80] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
97 Ha SY, Sohn I, Hwang SH, Yang JW, Park CK. The prognosis of hepatocellular carcinoma after curative hepatectomy in young patients. Oncotarget 2015;6:18664-73. [PMID: 26093092 DOI: 10.18632/oncotarget.4330] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
98 Van Renne N, Roca Suarez AA, Duong FHT, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut. 2018;67:953-962. [PMID: 28159835 DOI: 10.1136/gutjnl-2016-312270] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
99 Song BN, Chu IS. A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma. Exp Mol Med 2018;50:e418. [PMID: 29303511 DOI: 10.1038/emm.2017.159] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
100 Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology. 2012;55:1443-1452. [PMID: 22105560 DOI: 10.1002/hep.24813] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 8.8] [Reference Citation Analysis]
101 Cheng WC, Shu WY, Li CY, Tsai ML, Chang CW, Chen CR, Cheng HT, Wang TH, Hsu IC. Intra- and inter-individual variance of gene expression in clinical studies. PLoS One 2012;7:e38650. [PMID: 22723873 DOI: 10.1371/journal.pone.0038650] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
102 Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, Taouli B, Chung RT, Hoshida Y. Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clin Transl Gastroenterol 2017;8:e101. [PMID: 28640287 DOI: 10.1038/ctg.2017.26] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 16.0] [Reference Citation Analysis]
103 Zhu M, Lu T, Jia Y, Luo X, Gopal P, Li L, Odewole M, Renteria V, Singal AG, Jang Y, Ge K, Wang SC, Sorouri M, Parekh JR, MacConmara MP, Yopp AC, Wang T, Zhu H. Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic Liver Disease. Cell 2019;177:608-621.e12. [PMID: 30955891 DOI: 10.1016/j.cell.2019.03.026] [Cited by in Crossref: 77] [Cited by in F6Publishing: 57] [Article Influence: 38.5] [Reference Citation Analysis]
104 Das T, Diamond DL, Yeh M, Hassan S, Bryan JT, Reyes JD, Perkins JD. Molecular Signatures of Recurrent Hepatocellular Carcinoma Secondary to Hepatitis C Virus following Liver Transplantation. J Transplant 2013;2013:878297. [PMID: 24377043 DOI: 10.1155/2013/878297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
105 Verrier ER, Colpitts CC, Bach C, Heydmann L, Zona L, Xiao F, Thumann C, Crouchet E, Gaudin R, Sureau C, Cosset FL, McKeating JA, Pessaux P, Hoshida Y, Schuster C, Zeisel MB, Baumert TF. Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes. Cell Rep 2016;17:1357-68. [PMID: 27783949 DOI: 10.1016/j.celrep.2016.09.084] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
106 Hoshida Y. Molecular Epidemiology of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2012;1:177-9. [PMID: 26213618 DOI: 10.1002/cld.117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
107 Duan JL, Nie RC, Xiang ZC, Chen JW, Deng MH, Liang H, Wang FW, Luo RZ, Xie D, Cai MY. Prognostic Model for the Risk Stratification of Early and Late Recurrence in Hepatitis B Virus-Related Small Hepatocellular Carcinoma Patients with Global Histone Modifications. J Hepatocell Carcinoma 2021;8:493-505. [PMID: 34095004 DOI: 10.2147/JHC.S309451] [Reference Citation Analysis]
108 Lee SC, Tan HT, Chung MC. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. World J Gastroenterol. 2014;20:3112-3124. [PMID: 24696598 DOI: 10.3748/wjg.v20.i12.3112] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 52] [Article Influence: 8.8] [Reference Citation Analysis]
109 Bai Y, Lian Y, Chen X, Wu J, Lai J, Qiu F, Zhou S, Zhu Z, Tian Y, Wang Y, Yang Y, Yan M. Immunohistochemical Signature Add Prognostic Value in Patients With Early and Intermediate Hepatocellular Carcinoma Underwent Curative Liver Resection. Front Oncol 2020;10:616263. [PMID: 33585243 DOI: 10.3389/fonc.2020.616263] [Reference Citation Analysis]
110 Hernandez-Meza G, von Felden J, Gonzalez-Kozlova EE, Garcia-Lezana T, Peix J, Portela A, Craig AJ, Sayols S, Schwartz M, Losic B, Mazzaferro V, Esteller M, Llovet JM, Villanueva A. DNA Methylation Profiling of Human Hepatocarcinogenesis. Hepatology 2021;74:183-99. [PMID: 33237575 DOI: 10.1002/hep.31659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
111 Formeister EJ, Tsuchiya M, Fujii H, Shpyleva S, Pogribny IP, Rusyn I. Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res 2010;692:26-33. [PMID: 20736025 DOI: 10.1016/j.mrfmmm.2010.07.013] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
112 Zou H, Liao M, Xu W, Yao R, Liao W. Data mining of the expression and regulatory role of BCAT1 in hepatocellular carcinoma. Oncol Lett 2019;18:5879-88. [PMID: 31788061 DOI: 10.3892/ol.2019.10932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
113 Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol. 2015;7:139-149. [PMID: 25729470 DOI: 10.4254/wjh.v7.i2.139] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
114 Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250-261. [PMID: 31954490 DOI: 10.1016/j.jhep.2019.08.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 116] [Article Influence: 131.0] [Reference Citation Analysis]
115 Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, Do IG, Joh JW, Kim DS. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res 2009;28:20. [PMID: 19216803 DOI: 10.1186/1756-9966-28-20] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 5.4] [Reference Citation Analysis]
116 Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung SN, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Schwartz ME, Llovet JM. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011;140:1501-12.e2. [PMID: 21320499 DOI: 10.1053/j.gastro.2011.02.006] [Cited by in Crossref: 254] [Cited by in F6Publishing: 238] [Article Influence: 25.4] [Reference Citation Analysis]
117 Tan PS, Nakagawa S, Goossens N, Venkatesh A, Huang T, Ward SC, Sun X, Song WM, Koh A, Canasto-Chibuque C. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int. 2016;36:108-118. [PMID: 26058462 DOI: 10.1111/liv.12889] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
118 Kojima K, April C, Canasto-Chibuque C, Chen X, Deshmukh M, Venkatesh A, Tan PS, Kobayashi M, Kumada H, Fan JB. Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS One. 2014;9:e86961. [PMID: 24498002 DOI: 10.1371/journal.pone.0086961] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
119 Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2012;1:71-82. [PMID: 24159575 DOI: 10.1159/00034240] [Reference Citation Analysis]
120 Kebschull M, Hülsmann C, Hoffmann P, Papapanou PN. Genome-Wide Analysis of Periodontal and Peri-Implant Cells and Tissues. Methods Mol Biol 2017;1537:307-26. [PMID: 27924602 DOI: 10.1007/978-1-4939-6685-1_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
121 Man Z, Chen Y, Gao L, Xei G, Li Q, Lu Q, Yan J. A Prognostic Model Based on RNA Binding Protein Predicts Clinical Outcomes in Hepatocellular Carcinoma Patients. Front Oncol 2020;10:613102. [PMID: 33643914 DOI: 10.3389/fonc.2020.613102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol. 2010;52:921-929. [PMID: 20385424 DOI: 10.1016/j.jhep.2009.12.034] [Cited by in Crossref: 120] [Cited by in F6Publishing: 109] [Article Influence: 10.9] [Reference Citation Analysis]
123 Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, Browning JL, Goossens N, Nakagawa S, Gunasekaran G. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16:1235-1244. [PMID: 26502405 DOI: 10.1038/ni.3290] [Cited by in Crossref: 141] [Cited by in F6Publishing: 130] [Article Influence: 23.5] [Reference Citation Analysis]
124 Chen F. JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer Res. 2012;72:379-386. [PMID: 22253282 DOI: 10.1158/0008-5472.CAN-11-1982] [Cited by in Crossref: 139] [Cited by in F6Publishing: 72] [Article Influence: 15.4] [Reference Citation Analysis]
125 Stopsack KH, Gerke TA, Andrén O, Andersson SO, Giovannucci EL, Mucci LA, Rider JR. Cholesterol uptake and regulation in high-grade and lethal prostate cancers. Carcinogenesis 2017;38:806-11. [PMID: 28595267 DOI: 10.1093/carcin/bgx058] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 12.8] [Reference Citation Analysis]
126 Xue F, Higgs BW, Huang J, Morehouse C, Zhu W, Yao X, Brohawn P, Xiao Z, Sebastian Y, Liu Z, Xia Y, Shen D, Kuziora M, Dong Z, Han H, Gu Y, Gu J, Xia Q, Yao Y. HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma. J Transl Med 2015;13:379. [PMID: 26653219 DOI: 10.1186/s12967-015-0743-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
127 Ma X, Gu J, Wang K, Zhang X, Bai J, Zhang J, Liu C, Qiu Q, Qu K. Identification of a molecular subtyping system associated with the prognosis of Asian hepatocellular carcinoma patients receiving liver resection. Sci Rep 2019;9:7073. [PMID: 31068611 DOI: 10.1038/s41598-019-43548-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
128 Du Y, Han X, Ding YB, Yin JH, Cao GW. Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects. World J Gastroenterol 2016;22:6565-72. [PMID: 27547000 DOI: 10.3748/wjg.v22.i29.6565] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
129 Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, Hobbs GS, Quaas A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, Duda DG. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer 2020;8:e001435. [PMID: 33234602 DOI: 10.1136/jitc-2020-001435] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
130 Ahn SM, Haq F, Park I, Nault JC, Zucman-Rossi J, Yu E. The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma. BMC Cancer 2018;18:571. [PMID: 29776391 DOI: 10.1186/s12885-018-4192-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
131 Yu JH, Kim JM, Kim JK, Choi SJ, Lee KS, Lee JW, Chang HY, Lee JI. Platelet-derived growth factor receptor α in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis. Oncotarget 2017;8:39534-46. [PMID: 28465473 DOI: 10.18632/oncotarget.17134] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
132 Liu H, Liu W, Liu Z, Liu Y, Zhang W, Xu L, Xu J. Prognostic value of purinergic P2X7 receptor expression in patients with hepatocellular carcinoma after curative resection. Tumour Biol 2015;36:5039-49. [PMID: 25722111 DOI: 10.1007/s13277-015-3155-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
133 Zhang DY, Goossens N, Guo J, Tsai MC, Chou HI, Altunkaynak C, Sangiovanni A, Iavarone M, Colombo M, Kobayashi M. A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut. 2016;65:1754-1764. [PMID: 26045137 DOI: 10.1136/gutjnl-2015-309655] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 10.5] [Reference Citation Analysis]
134 Ha SY, Choi M, Lee T, Park CK. The Prognostic Role of Mitotic Index in Hepatocellular Carcinoma Patients after Curative Hepatectomy. Cancer Res Treat. 2016;48:180-189. [PMID: 25797572 DOI: 10.4143/crt.2014.321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
135 Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2012;1:71-82. [PMID: 24159575 DOI: 10.1159/000342403] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 7.7] [Reference Citation Analysis]
136 Dasgupta S, Jang JS, Shao C, Mukhopadhyay ND, Sokhi UK, Das SK, Brait M, Talbot C, Yung RC, Begum S, Westra WH, Hoque MO, Yang P, Yi JE, Lam S, Gazdar AF, Fisher PB, Jen J, Sidransky D. SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling. J Mol Med (Berl) 2013;91:381-93. [PMID: 22968441 DOI: 10.1007/s00109-012-0955-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
137 Jiang J, Zheng Q, Zhu W, Chen X, Lu H, Chen D, Zhang H, Shao M, Zhou L, Zheng S. Alterations in glycolytic/cholesterogenic gene expression in hepatocellular carcinoma. Aging (Albany NY) 2020;12:10300-16. [PMID: 32479426 DOI: 10.18632/aging.103254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
138 Wang H, Wang X, Xu L, Zhang J, Cao H. Integrated analysis of the E2F transcription factors across cancer types. Oncol Rep 2020;43:1133-46. [PMID: 32323836 DOI: 10.3892/or.2020.7504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
139 Fan ST. Hepatocellular carcinoma--resection or transplant? Nat Rev Gastroenterol Hepatol 2012;9:732-7. [PMID: 22965432 DOI: 10.1038/nrgastro.2012.158] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
140 Wu L, Claas AM, Sarkar A, Lauffenburger DA, Han J. High-throughput protease activity cytometry reveals dose-dependent heterogeneity in PMA-mediated ADAM17 activation. Integr Biol (Camb) 2015;7:513-24. [PMID: 25832727 DOI: 10.1039/c5ib00019j] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
141 Kim BY, Choi DW, Woo SR, Park ER, Lee JG, Kim SH, Koo I, Park SH, Han CJ, Kim SB, Yeom YI, Yang SJ, Yu A, Lee JW, Jang JJ, Cho MH, Jeon WK, Park YN, Suh KS, Lee KH. Recurrence-associated pathways in hepatitis B virus-positive hepatocellular carcinoma. BMC Genomics 2015;16:279. [PMID: 25888140 DOI: 10.1186/s12864-015-1472-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
142 Van Hees S, Michielsen P, Vanwolleghem T. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2016;22:8271-8282. [PMID: 27729734 DOI: 10.3748/wjg.v22.i37.8271] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
143 Chen VL, Le AK, Podlaha O, Estevez J, Li B, Vutien P, Chang ET, Rosenberg-Hasson Y, Pflanz S, Jiang Z, Ge D, Gaggar A, Nguyen MH. Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk: multiplex analysis of serum markers. Sci Rep. 2017;7:11169. [PMID: 28894136 DOI: 10.1038/s41598-017-10498-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
144 Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, Wang XW. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70:10202-10212. [PMID: 21159642 DOI: 10.1158/0008-5472.can-10-2607] [Cited by in Crossref: 478] [Cited by in F6Publishing: 354] [Article Influence: 47.8] [Reference Citation Analysis]
145 Rickman DS, Chen YB, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR, Sircar K, Chinnaiyan AM, Bismar TA, Rubin MA, Demichelis F. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 2010;12:1031-40. [PMID: 21170267 DOI: 10.1593/neo.10866] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
146 Yan P, Huang Z, Mou T, Luo Y, Liu Y, Zhou B, Cao Z, Wu Z. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence. BMC Cancer 2021;21:436. [PMID: 33879119 DOI: 10.1186/s12885-021-08173-0] [Reference Citation Analysis]
147 Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology 2019;157:54-64. [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049] [Cited by in Crossref: 94] [Cited by in F6Publishing: 72] [Article Influence: 47.0] [Reference Citation Analysis]
148 Zhang Y, Wang S, Li D, Zhnag J, Gu D, Zhu Y, He F. A systems biology-based classifier for hepatocellular carcinoma diagnosis. PLoS One 2011;6:e22426. [PMID: 21829460 DOI: 10.1371/journal.pone.0022426] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
149 van der Stok EP, Smid M, Sieuwerts AM, Vermeulen PB, Sleijfer S, Ayez N, Grünhagen DJ, Martens JW, Verhoef C. mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy. Mol Oncol 2016;10:1542-50. [PMID: 27692894 DOI: 10.1016/j.molonc.2016.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
150 Iwakiri Y, Kim MY. Nitric oxide in liver diseases. Trends Pharmacol Sci. 2015;36:524-536. [PMID: 26027855 DOI: 10.1016/j.tips.2015.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 73] [Article Influence: 17.2] [Reference Citation Analysis]
151 Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology 2019;156:492-509. [PMID: 30404026 DOI: 10.1053/j.gastro.2018.11.001] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 21.7] [Reference Citation Analysis]
152 Yamashita T, Kitao A, Matsui O, Hayashi T, Nio K, Kondo M, Ohno N, Miyati T, Okada H, Yamashita T, Mizukoshi E, Honda M, Nakanuma Y, Takamura H, Ohta T, Nakamoto Y, Yamamoto M, Takayama T, Arii S, Wang X, Kaneko S. Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology. 2014;60:1674-1685. [PMID: 24700365 DOI: 10.1002/hep.27093] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 9.7] [Reference Citation Analysis]
153 Yu W, Rong W, Wang L, Wu F, Xu Q, Wu J. R1 hepatectomy with exposure of tumor surface for centrally located hepatocellular carcinoma. World J Surg. 2014;38:1777-1785. [PMID: 24370545 DOI: 10.1007/s00268-013-2429-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
154 Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR. Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Res 2016;76:4785-90. [PMID: 27325648 DOI: 10.1158/0008-5472.CAN-16-0903] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 7.4] [Reference Citation Analysis]
155 Yüksel Ş, Boylu Akyerli C, Cengiz Yakıcıer M. Angiogenesis, Invasion, and Metastasis Characteristics of Hepatocellular Carcinoma. J Gastrointest Cancer 2017;48:256-9. [PMID: 28785955 DOI: 10.1007/s12029-017-9962-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
156 LE PH, Huang SC, Lim SN, Chou CH, Yeh TS, Chen TC, Yen TH, Su MY, Chiu CT, Yeh CT, Lin WR. Complex IV subunit 1 defect predicts postoperative survival in hepatocellular carcinoma. Oncol Lett 2014;7:1430-8. [PMID: 24765151 DOI: 10.3892/ol.2014.1966] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
157 Fakhri B, Lim KH. Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature. J Gastrointest Oncol. 2017;8:379-386. [PMID: 28736626 DOI: 10.21037/jgo.2016.11.01] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
158 April C, Klotzle B, Royce T, Wickham-Garcia E, Boyaniwsky T, Izzo J, Cox D, Jones W, Rubio R, Holton K. Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS One. 2009;4:e8162. [PMID: 19997620 DOI: 10.1371/journal.pone.0008162] [Cited by in Crossref: 91] [Cited by in F6Publishing: 83] [Article Influence: 7.6] [Reference Citation Analysis]
159 Zhu P, Jin J, Liao Y, Li J, Yu XZ, Liao W, He S. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma. Oncotarget 2015;6:41383-97. [PMID: 26515591 DOI: 10.18632/oncotarget.5510] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
160 El-Shamy A, Eng FJ, Doyle EH, Klepper AL, Sun X, Sangiovanni A, Iavarone M, Colombo M, Schwartz RE, Hoshida Y, Branch AD. A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. J Hepatol 2015;63:1323-33. [PMID: 26220749 DOI: 10.1016/j.jhep.2015.07.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
161 Cai X, Zhai J, Kaplan DE, Zhang Y, Zhou L, Chen X, Qian G, Zhao Q, Li Y, Gao L, Cong W, Zhu M, Yan Z, Shi L, Wu D, Wei L, Shen F, Wu M. Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma. Hepatology. 2012;56:1804-1816. [PMID: 22684921 DOI: 10.1002/hep.25874] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 5.7] [Reference Citation Analysis]
162 Fujiwara N, Hoshida Y. Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis. Semin Liver Dis 2019;39:153-62. [PMID: 30912093 DOI: 10.1055/s-0039-1681031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
163 Grinchuk OV, Yenamandra SP, Iyer R, Singh M, Lee HK, Lim KH, Chow PK, Kuznetsov VA. Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma. Mol Oncol 2018;12:89-113. [PMID: 29117471 DOI: 10.1002/1878-0261.12153] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
164 Xie Y, Xiao G, Coombes KR, Behrens C, Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, Moran C, Danenberg K, Minna JD, Wistuba II. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res 2011;17:5705-14. [PMID: 21742808 DOI: 10.1158/1078-0432.CCR-11-0196] [Cited by in Crossref: 98] [Cited by in F6Publishing: 64] [Article Influence: 9.8] [Reference Citation Analysis]
165 Elizalde M, Urtasun R, Azkona M, Latasa MU, Goñi S, García-Irigoyen O, Uriarte I, Segura V, Collantes M, Di Scala M, Lujambio A, Prieto J, Ávila MA, Berasain C. Splicing regulator SLU7 is essential for maintaining liver homeostasis. J Clin Invest 2014;124:2909-20. [PMID: 24865429 DOI: 10.1172/JCI74382] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
166 Ang C, Doyle E, Branch A. Bisphosphonates as potential adjuvants for patients with cancers of the digestive system. World J Gastroenterol 2016;22:906-16. [PMID: 26811636 DOI: 10.3748/wjg.v22.i3.906] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
167 Kudo Y, Sugimoto M, Arias E, Kasashima H, Cordes T, Linares JF, Duran A, Nakanishi Y, Nakanishi N, L'Hermitte A, Campos A, Senni N, Rooslid T, Roberts LR, Cuervo AM, Metallo CM, Karin M, Diaz-Meco MT, Moscat J. PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression. Cancer Cell 2020;38:247-262.e11. [PMID: 32589943 DOI: 10.1016/j.ccell.2020.05.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
168 Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 2012;61:427-438. [PMID: 21930732 DOI: 10.1136/gutjnl-2011-300509] [Cited by in Crossref: 192] [Cited by in F6Publishing: 176] [Article Influence: 19.2] [Reference Citation Analysis]
169 Llovet JM, Paradis V, Kudo M, Zucman-Rossi J. Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl. 2011;17 Suppl 2:S67-S71. [PMID: 21594967 DOI: 10.1002/lt.22340] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
170 Bakiri L, Wagner EF. Mouse models for liver cancer. Mol Oncol 2013;7:206-23. [PMID: 23428636 DOI: 10.1016/j.molonc.2013.01.005] [Cited by in Crossref: 107] [Cited by in F6Publishing: 90] [Article Influence: 13.4] [Reference Citation Analysis]
171 Hao K, Luk JM, Lee NP, Mao M, Zhang C, Ferguson MD, Lamb J, Dai H, Ng IO, Sham PC. Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer. 2009;9:389. [PMID: 19886989 DOI: 10.1186/1471-2407-9-389] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 7.0] [Reference Citation Analysis]
172 Kwon SM, Cho H, Choi JH, Jee BA, Jo Y, Woo HG. Perspectives of integrative cancer genomics in next generation sequencing era. Genomics Inform 2012;10:69-73. [PMID: 23105932 DOI: 10.5808/GI.2012.10.2.69] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
173 Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol 2010;53:568-77. [PMID: 20646772 DOI: 10.1016/j.jhep.2010.05.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
174 Chen IP, Ariizumi S, Nakano M, Yamamoto M. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol 2014;49:117-25. [PMID: 23532638 DOI: 10.1007/s00535-013-0793-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
175 Nault JC. Molecular Determinants of Prognosis in Hepatocellular Carcinoma. J Clin Transl Hepatol 2014;2:31-6. [PMID: 26357615 DOI: 10.14218/JCTH.2013.00029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 Waisberg J, Saba GT. Wnt-/-β-catenin pathway signaling in human hepatocellular carcinoma. World J Hepatol 2015;7:2631-5. [PMID: 26609340 DOI: 10.4254/wjh.v7.i26.2631] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
177 Gong J, Chuang J, Cho M, Toomey K, Hendifar A, Li D. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5232. [PMID: 32718047 DOI: 10.3390/ijms21155232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Domovitz T, Gal-Tanamy M. Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis. J Clin Med 2021;10:551. [PMID: 33540858 DOI: 10.3390/jcm10030551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
179 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 239] [Article Influence: 43.3] [Reference Citation Analysis]
180 Ao L, Zhang Z, Guan Q, Guo Y, Guo Y, Zhang J, Lv X, Huang H, Zhang H, Wang X, Guo Z. A qualitative signature for early diagnosis of hepatocellular carcinoma based on relative expression orderings. Liver Int 2018;38:1812-9. [PMID: 29682909 DOI: 10.1111/liv.13864] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
181 Sapisochin G, Bilbao I, Balsells J, Dopazo C, Caralt M, Lázaro JL, Castells L, Allende H, Charco R. Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series. World J Surg 2010;34:2146-54. [PMID: 20411387 DOI: 10.1007/s00268-010-0583-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
182 Jung CJ, Iyengar S, Blahnik KR, Jiang JX, Tahimic C, Torok NJ, de vere White RW, Farnham PJ, Zern M. Human ESC self-renewal promoting microRNAs induce epithelial-mesenchymal transition in hepatocytes by controlling the PTEN and TGFβ tumor suppressor signaling pathways. Mol Cancer Res 2012;10:979-91. [PMID: 22622027 DOI: 10.1158/1541-7786.MCR-11-0421] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
183 Afshar M, Fletcher P, Bardoli AD, Ma YT, Punia P. Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort. Oncotarget 2018;9:16988-95. [PMID: 29682199 DOI: 10.18632/oncotarget.24769] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
184 Cariani E, Pilli M, Zerbini A, Rota C, Olivani A, Pelosi G, Schianchi C, Soliani P, Campanini N, Silini EM, Trenti T, Ferrari C, Missale G. Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS One 2012;7:e32493. [PMID: 22396772 DOI: 10.1371/journal.pone.0032493] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 5.6] [Reference Citation Analysis]
185 Dekervel J, Popovic D, van Malenstein H, Windmolders P, Heylen L, Libbrecht L, Bulle A, De Moor B, Van Cutsem E, Nevens F, Verslype C, van Pelt J. A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular Carcinoma. Transl Oncol 2016;9:139-46. [PMID: 27084430 DOI: 10.1016/j.tranon.2016.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
186 Hyeon J, Ahn S, Park CK. CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection. Korean J Pathol. 2013;47:9-15. [PMID: 23482400 DOI: 10.4132/koreanjpathol.2013.47.1.9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
187 Hoshida Y. Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS One 2010;5:e15543. [PMID: 21124904 DOI: 10.1371/journal.pone.0015543] [Cited by in Crossref: 114] [Cited by in F6Publishing: 92] [Article Influence: 10.4] [Reference Citation Analysis]
188 Chen X, Liao Y, Yu Y, Zhu P, Li J, Qin L, Liao W, Huang Z. Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma. Oncotarget 2017;8:92589-603. [PMID: 29190940 DOI: 10.18632/oncotarget.21506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
189 Wang L, Huang J, Jiang M, Zheng X. AFP computational secreted network construction and analysis between human hepatocellular carcinoma (HCC) and no-tumor hepatitis/cirrhotic liver tissues. Tumour Biol. 2010;31:417-425. [PMID: 20532728 DOI: 10.1007/s13277-010-0050-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
190 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 294] [Article Influence: 31.0] [Reference Citation Analysis]
191 Kibriya MG, Jasmine F, Roy S, Paul-Brutus RM, Argos M, Ahsan H. Analyses and interpretation of whole-genome gene expression from formalin-fixed paraffin-embedded tissue: an illustration with breast cancer tissues. BMC Genomics 2010;11:622. [PMID: 21059268 DOI: 10.1186/1471-2164-11-622] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
192 Labgaa I, Villanueva A, Dormond O, Demartines N, Melloul E. The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers (Basel) 2021;13:659. [PMID: 33562173 DOI: 10.3390/cancers13040659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
193 Cauchy F, Fuks D, Belghiti J. HCC: current surgical treatment concepts. Langenbecks Arch Surg 2012;397:681-95. [DOI: 10.1007/s00423-012-0911-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
194 Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010;16:4688-94. [PMID: 20713493 DOI: 10.1158/1078-0432.CCR-09-1811] [Cited by in Crossref: 92] [Cited by in F6Publishing: 58] [Article Influence: 8.4] [Reference Citation Analysis]
195 Bendall SC, Nolan GP. From single cells to deep phenotypes in cancer. Nat Biotechnol. 2012;30:639-647. [PMID: 22781693 DOI: 10.1038/nbt.2283] [Cited by in Crossref: 169] [Cited by in F6Publishing: 142] [Article Influence: 18.8] [Reference Citation Analysis]
196 Russo A, Caltabiano R, Longo A, Avitabile T, Franco LM, Bonfiglio V, Puzzo L, Reibaldi M. Increased Levels of miRNA-146a in Serum and Histologic Samples of Patients with Uveal Melanoma. Front Pharmacol 2016;7:424. [PMID: 27895580 DOI: 10.3389/fphar.2016.00424] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
197 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol. 2016;22:232-252. [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
198 Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, Mucci LA, Kantoff PW, Stampfer M, Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub TR, Rubin MA, Andrén O. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010;3:8. [PMID: 20233430 DOI: 10.1186/1755-8794-3-8] [Cited by in Crossref: 155] [Cited by in F6Publishing: 137] [Article Influence: 14.1] [Reference Citation Analysis]
199 Wu HQ, Cheng ML, Lai JM, Wu HH, Chen MC, Liu WH, Wu WH, Chang PM, Huang CF, Tsou AP, Shiao MS, Wang FS. Flux balance analysis predicts Warburg-like effects of mouse hepatocyte deficient in miR-122a. PLoS Comput Biol 2017;13:e1005618. [PMID: 28686599 DOI: 10.1371/journal.pcbi.1005618] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
200 Wee A. Fine-needle aspiration biopsy of hepatocellular carcinoma and related hepatocellular nodular lesions in cirrhosis: controversies, challenges, and expectations. Patholog Res Int 2011;2011:587936. [PMID: 21789263 DOI: 10.4061/2011/587936] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
201 Komposch K, Sibilia M. EGFR Signaling in Liver Diseases. Int J Mol Sci 2015;17:E30. [PMID: 26729094 DOI: 10.3390/ijms17010030] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 12.7] [Reference Citation Analysis]
202 Sadi AM, Wang DY, Youngson BJ, Miller N, Boerner S, Done SJ, Leong WL. Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens. BMC Cancer. 2011;11:253: 1-25313. [PMID: 21679412 DOI: 10.1186/1471-2407-11-253] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
203 Jung HY, Kim SH, Jing J, Gwak JM, Han CJ, Jang JJ, Lee KB. The Histologic Cut-off Point for Adjacent and Remote Non-neoplastic Liver Parenchyma of Hepatocellular Carcinoma in Chronic Hepatitis B Patients. Korean J Pathol 2012;46:349-58. [PMID: 23110027 DOI: 10.4132/KoreanJPathol.2012.46.4.349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
204 Chen Z, Lu X, Wang Z, Jin G, Wang Q, Chen D, Chen T, Li J, Fan J, Cong W. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma. Oncotarget. 2015;6:2538-2548. [PMID: 25576919 DOI: 10.18632/oncotarget.2991] [Cited by in Crossref: 22] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
205 Macek Jilkova Z, Aspord C, Decaens T. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers (Basel) 2019;11:E1554. [PMID: 31615069 DOI: 10.3390/cancers11101554] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 12.5] [Reference Citation Analysis]
206 Castelli G, Pelosi E, Testa U. Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel) 2017;9:E127. [PMID: 28930164 DOI: 10.3390/cancers9090127] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 11.8] [Reference Citation Analysis]
207 Ribeiro OD, Canedo NH, Pannain VL. Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features. Clinics (Sao Paulo) 2016;71:639-43. [PMID: 27982164 DOI: 10.6061/clinics/2016(11)04] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
208 Makarov DV, Isharwal S, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 2009;15:7316-21. [PMID: 19934305 DOI: 10.1158/1078-0432.CCR-09-1263] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
209 Delire B, Henriet P, Lemoine P, Leclercq IA, Stärkel P. Chronic liver injury promotes hepatocarcinoma cell seeding and growth, associated with infiltration by macrophages. Cancer Sci 2018;109:2141-52. [PMID: 29727510 DOI: 10.1111/cas.13628] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
210 Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget. 2016;7:25087-25102. [PMID: 26943571 DOI: 10.18632/oncotarget.7837] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
211 Ye F, Jing YY, Guo SW, Yu GF, Fan QM, Qu FF, Gao L, Yang Y, Wu D, Meng Y, Yu FH, Wei LX. Proliferative ductular reactions correlate with hepatic progenitor cell and predict recurrence in HCC patients after curative resection. Cell Biosci 2014;4:50. [PMID: 25197550 DOI: 10.1186/2045-3701-4-50] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
212 Chang Q, Chen J, Beezhold KJ, Castranova V, Shi X, Chen F. JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer 2009;8:64. [PMID: 19686584 DOI: 10.1186/1476-4598-8-64] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
213 Noordam L, Ge Z, Özturk H, Doukas M, Mancham S, Boor PPC, Campos Carrascosa L, Zhou G, van den Bosch TPP, Pan Q, IJzermans JNM, Bruno MJ, Sprengers D, Kwekkeboom J. Expression of Cancer Testis Antigens in Tumor-Adjacent Normal Liver Is Associated with Post-Resection Recurrence of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2499. [PMID: 34065388 DOI: 10.3390/cancers13102499] [Reference Citation Analysis]
214 Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM. Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol. 2017;27:4472-4481. [PMID: 28439654 DOI: 10.1007/s00330-017-4844-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
215 Roy HK, Brendler CB, Subramanian H, Zhang D, Maneval C, Chandler J, Bowen L, Kaul KL, Helfand BT, Wang CH, Quinn M, Petkewicz J, Paterakos M, Backman V. Nanocytological field carcinogenesis detection to mitigate overdiagnosis of prostate cancer: a proof of concept study. PLoS One 2015;10:e0115999. [PMID: 25706755 DOI: 10.1371/journal.pone.0115999] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
216 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 176] [Article Influence: 49.5] [Reference Citation Analysis]
217 Bozward AG, Warricker F, Oo YH, Khakoo SI. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. Front Immunol 2021;12:643310. [PMID: 33995362 DOI: 10.3389/fimmu.2021.643310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
218 Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol 2015;2:371-9. [PMID: 26617981 DOI: 10.2217/hep.15.26] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 10.5] [Reference Citation Analysis]
219 Leung J, Wei W, Liu L. S-nitrosoglutathione reductase deficiency increases mutagenesis from alkylation in mouse liver. Carcinogenesis 2013;34:984-9. [PMID: 23354311 DOI: 10.1093/carcin/bgt031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
220 Goossens N, Hoshida Y. Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis (Hoboken) 2015;5:132-5. [PMID: 26213619 DOI: 10.1002/cld.483] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
221 Alnajjar KS, Sweasy JB. A new perspective on oxidation of DNA repair proteins and cancer. DNA Repair (Amst) 2019;76:60-9. [PMID: 30818170 DOI: 10.1016/j.dnarep.2019.02.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
222 Liu W, Ye H, Liu YF, Xu CQ, Zhong YX, Tian T, Ma SW, Tao H, Li L, Xue LC, He HQ. Transcriptome-derived stromal and immune scores infer clinical outcomes of patients with cancer. Oncol Lett. 2018;15:4351-4357. [PMID: 29541203 DOI: 10.3892/ol.2018.7855] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
223 Suenaga M, Yamada S, Fujii T, Fuchs BC, Okumura N, Kanda M, Kobayashi D, Tanaka C, Nakayama G, Sugimoto H. A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. Onco Targets Ther. 2013;6:1805-1812. [PMID: 24363559 DOI: 10.2147/ott.s53625] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
224 Lee J, Sohn I, Do IG, Kim KM, Park SH, Park JO, Park YS, Lim HY, Sohn TS, Bae JM, Choi MG, Lim DH, Min BH, Lee JH, Rhee PL, Kim JJ, Choi DI, Tan IB, Das K, Tan P, Jung SH, Kang WK, Kim S. Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS One. 2014;9:e90133. [PMID: 24598828 DOI: 10.1371/journal.pone.0090133] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 8.6] [Reference Citation Analysis]
225 Mebarki S, Désert R, Sulpice L, Sicard M, Desille M, Canal F, Dubois-Pot Schneider H, Bergeat D, Turlin B, Bellaud P, Lavergne E, Le Guével R, Corlu A, Perret C, Coulouarn C, Clément B, Musso O. De novo HAPLN1 expression hallmarks Wnt-induced stem cell and fibrogenic networks leading to aggressive human hepatocellular carcinomas. Oncotarget 2016;7:39026-43. [PMID: 27191501 DOI: 10.18632/oncotarget.9346] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
226 Jia JB, Wang WQ, Sun HC, Zhu XD, Liu L, Zhuang PY, Zhang JB, Zhang W, Xu HX, Kong LQ, Lu L, Wu WZ, Wang L, Tang ZY. High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. Oncologist 2010;15:732-43. [PMID: 20551429 DOI: 10.1634/theoncologist.2009-0170] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
227 Tarocchi M, Hannivoort R, Hoshida Y, Lee UE, Vetter D, Narla G, Villanueva A, Oren M, Llovet JM, Friedman SL. Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology. 2011;54:522-531. [PMID: 21563203 DOI: 10.1002/hep.24413] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
228 Gopal R, Selvarasu K, Pandian PP, Ganesan K. Integrative transcriptome analysis of liver cancer profiles identifies upstream regulators and clinical significance of ACSM3 gene expression. Cell Oncol (Dordr) 2017;40:219-33. [PMID: 28390038 DOI: 10.1007/s13402-017-0321-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
229 Sonohara F, Inokawa Y, Hayashi M, Yamada S, Sugimoto H, Fujii T, Kodera Y, Nomoto S. Prognostic Value of Long Non-Coding RNA HULC and MALAT1 Following the Curative Resection of Hepatocellular Carcinoma. Sci Rep 2017;7:16142. [PMID: 29170515 DOI: 10.1038/s41598-017-16260-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
230 Frau M, Simile MM, Tomasi ML, Demartis MI, Daino L, Seddaiu MA, Brozzetti S, Feo CF, Massarelli G, Solinas G, Feo F, Lee JS, Pascale RM. An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis. Cell Oncol (Dordr) 2012;35:163-73. [PMID: 22434528 DOI: 10.1007/s13402-011-0067-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
231 Rombouts K, Carloni V. The fibrotic microenvironment as a heterogeneity facet of hepatocellular carcinoma. Fibrogenesis Tissue Repair 2013;6:17. [PMID: 24350713 DOI: 10.1186/1755-1536-6-17] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
232 Van Renne N, Wei R, Pochet N, Nauwynck HJ. Dissecting clinical outcome of porcine circovirus type 2 with in vivo derived transcriptomic signatures of host tissue responses. BMC Genomics 2018;19:831. [PMID: 30458705 DOI: 10.1186/s12864-018-5217-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
233 Carr BI, Pancoska P, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Marco MD, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters. Semin Oncol 2014;41:406-14. [PMID: 25023357 DOI: 10.1053/j.seminoncol.2014.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
234 Qin LX. Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma. Cancer Microenviron. 2012;5:203-209. [PMID: 22678823 DOI: 10.1007/s12307-012-0111-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
235 Li WQ, Han J, Widlund HR, Correll M, Wang YE, Quackenbush J, Mihm MC, Canales AL, Wu S, Golub T, Hoshida Y, Hunter DJ, Murphy G, Kupper TS, Qureshi AA. CXCR4 pathway associated with family history of melanoma. Cancer Causes Control 2014;25:125-32. [PMID: 24158781 DOI: 10.1007/s10552-013-0315-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
236 Li W, Wang H, Ma Z, Zhang J, Ou-Yang W, Qi Y, Liu J. Multi-omics Analysis of Microenvironment Characteristics and Immune Escape Mechanisms of Hepatocellular Carcinoma. Front Oncol. 2019;9:1019. [PMID: 31681571 DOI: 10.3389/fonc.2019.01019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
237 Reich HN, Landolt-Marticorena C, Boutros PC, John R, Wither J, Fortin PR, Yang S, Scholey JW, Herzenberg AM. Molecular markers of injury in kidney biopsy specimens of patients with lupus nephritis. J Mol Diagn 2011;13:143-51. [PMID: 21354048 DOI: 10.1016/j.jmoldx.2010.10.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
238 Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT; HALT-C Trial Group. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011;141:141-9. [PMID: 21440548 DOI: 10.1053/j.gastro.2011.03.045] [Cited by in Crossref: 100] [Cited by in F6Publishing: 74] [Article Influence: 10.0] [Reference Citation Analysis]
239 Shen Q, Yang XR, Tan Y, You H, Xu Y, Chu W, Ge T, Zhou J, Qiu SJ, Shi YH, Zhang Z, Gu J, Wang H, Fan J, Qin W. High level of serum protein DKK1 predicts poor prognosis for patients with hepatocellular carcinoma after hepatectomy. Hepat Oncol 2015;2:231-44. [PMID: 30191005 DOI: 10.2217/hep.15.12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
240 Cho E, Kim HC, Lee JH, Jeong-Ju Yoo WM, Cho YY, Lee MJ, Cho Y, Lee DH, Lee YB, Yu SJ. Serum insulin-like growth factor-1 predicts disease progression and survival in patients with hepatocellular carcinoma who undergo transarterial chemoembolization. PLoS One. 2014;9:e90862. [PMID: 24595361 DOI: 10.1371/journal.pone.0090862] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
241 Zheng J, Sadot E, Vigidal JA, Klimstra DS, Balachandran VP, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Jarnagin WR, Ventura A. Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing. PLoS One 2018;13:e0200776. [PMID: 30052636 DOI: 10.1371/journal.pone.0200776] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
242 Sfakianos GP, Iversen ES, Whitaker R, Akushevich L, Schildkraut JM, Murphy SK, Marks JR, Berchuck A. Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. Gynecol Oncol 2013;129:159-64. [PMID: 23274563 DOI: 10.1016/j.ygyno.2012.12.030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
243 Kitano Y, Okabe H, Yamashita YI, Nakagawa S, Saito Y, Umezaki N, Tsukamoto M, Yamao T, Yamamura K, Arima K, Kaida T, Miyata T, Mima K, Imai K, Hashimoto D, Komohara Y, Chikamoto A, Ishiko T, Baba H. Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma. Br J Cancer 2018;118:171-80. [PMID: 29123259 DOI: 10.1038/bjc.2017.401] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 10.5] [Reference Citation Analysis]
244 Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology. 2011;140:1618-1628.e16. [PMID: 21324318 DOI: 10.1053/j.gastro.2011.02.009] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 15.3] [Reference Citation Analysis]
245 Honda M, Yamashita T, Yamashita T, Arai K, Sakai Y, Sakai A, Nakamura M, Mizukoshi E, Kaneko S. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013;13:191. [PMID: 23587162 DOI: 10.1186/1471-2407-13-191] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
246 Akkiz H. The Emerging Role of MicroRNAs in Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2014;4:45-50. [PMID: 29264318 DOI: 10.5005/jp-journals-10018-1095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
247 Czauderna C, Castven D, Mahn FL, Marquardt JU. Context-Dependent Role of NF-κB Signaling in Primary Liver Cancer-from Tumor Development to Therapeutic Implications. Cancers (Basel) 2019;11:E1053. [PMID: 31349670 DOI: 10.3390/cancers11081053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
248 Yang JD, Malhi H. Green tea consumption: A potential chemopreventive measure for hepatocellular carcinoma? Hepatology 2018;67:10-2. [PMID: 28833368 DOI: 10.1002/hep.29481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
249 Hong R, Gu J, Niu G, Hu Z, Zhang X, Song T, Han S, Hong L, Ke C. PRELP has prognostic value and regulates cell proliferation and migration in hepatocellular carcinoma. J Cancer 2020;11:6376-89. [PMID: 33033521 DOI: 10.7150/jca.46309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
250 Ito H, Mo Q, Qin LX, Viale A, Maithel SK, Maker AV, Shia J, Kingham P, Allen P, DeMatteo RP, Fong Y, Jarnagin WR, D'Angelica M. Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer. PLoS One 2013;8:e81680. [PMID: 24339954 DOI: 10.1371/journal.pone.0081680] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
251 Sobrevals L, Enguita M, Quiroga J, Prieto J, Fortes P. Insulin-Like Growth Factor I (IGF-I) Expressed from an AAV1 Vector Leads to a Complete Reversion of Liver Cirrhosis in Rats. PLoS One 2016;11:e0162955. [PMID: 27658043 DOI: 10.1371/journal.pone.0162955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
252 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014;20:5935-50. [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 84] [Article Influence: 13.7] [Reference Citation Analysis]
253 Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2011;21:35-43. [PMID: 20946957 DOI: 10.1016/j.semcancer.2010.10.007] [Cited by in Crossref: 216] [Cited by in F6Publishing: 195] [Article Influence: 19.6] [Reference Citation Analysis]
254 O'Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World J Gastroenterol 2018;24:4436-47. [PMID: 30357021 DOI: 10.3748/wjg.v24.i39.4436] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 39] [Article Influence: 26.0] [Reference Citation Analysis]
255 Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011;55:1325-31. [PMID: 21703203 DOI: 10.1016/j.jhep.2011.02.034] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 9.3] [Reference Citation Analysis]
256 Bruno S, Savojardo D, Almasio PL, Mondelli MU. Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med 2011;3:21-8. [PMID: 24367218 DOI: 10.2147/HMER.S16991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
257 Protiva P, Gong J, Sreekumar B, Torres R, Zhang X, Belinsky GS, Cornwell M, Crawford SE, Iwakiri Y, Chung C. Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/β-catenin Signaling in the Liver. Cell Mol Gastroenterol Hepatol 2015;1:535-549.e14. [PMID: 26473164 DOI: 10.1016/j.jcmgh.2015.06.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
258 Huang T, Wang J, Cai YD, Yu H, Chou KC. Hepatitis C virus network based classification of hepatocellular cirrhosis and carcinoma. PLoS One 2012;7:e34460. [PMID: 22493692 DOI: 10.1371/journal.pone.0034460] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
259 Rókusz A, Veres D, Szücs A, Bugyik E, Mózes M, Paku S, Nagy P, Dezső K. Ductular reaction correlates with fibrogenesis but does not contribute to liver regeneration in experimental fibrosis models. PLoS One 2017;12:e0176518. [PMID: 28445529 DOI: 10.1371/journal.pone.0176518] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
260 Liao R, Wu H, Yi Y, Wang JX, Cai XY, He HW, Cheng YF, Zhou J, Fan J, Sun J, Qiu SJ. Clinical significance and gene expression study of human hepatic stellate cells in HBV related-hepatocellular carcinoma. J Exp Clin Cancer Res 2013;32:22. [PMID: 23601182 DOI: 10.1186/1756-9966-32-22] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
261 Ahn S, Hyeon J, Park CK. Metadherin is a prognostic predictor of hepatocellular carcinoma after curative hepatectomy. Gut Liver 2013;7:206-12. [PMID: 23560157 DOI: 10.5009/gnl.2013.7.2.206] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
262 Xie Q, Su Y, Dykema K, Johnson J, Koeman J, De Giorgi V, Huang A, Schlegel R, Essenburg C, Kang L, Iwaya K, Seki S, Khoo SK, Zhang B, Buonaguro F, Marincola FM, Furge K, Vande Woude GF, Shinomiya N. Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes Cancer 2013;4:247-60. [PMID: 24167653 DOI: 10.1177/1947601913501075] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
263 Malik A, Thanekar U, Amarachintha S, Mourya R, Nalluri S, Bondoc A, Shivakumar P. "Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. Front Oncol 2020;10:627701. [PMID: 33718121 DOI: 10.3389/fonc.2020.627701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
264 Tang CH, Wei W, Hanes MA, Liu L. Hepatocarcinogenesis driven by GSNOR deficiency is prevented by iNOS inhibition. Cancer Res 2013;73:2897-904. [PMID: 23440427 DOI: 10.1158/0008-5472.CAN-12-3980] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
265 Kannan A, Philley JV, Hertweck KL, Ndetan H, Singh KP, Sivakumar S, Wells RB, Vadlamudi RK, Dasgupta S. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles. Sci Rep 2019;9:11632. [PMID: 31406142 DOI: 10.1038/s41598-019-48064-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
266 Zhong X, Kan A, Zhang W, Zhou J, Zhang H, Chen J, Tang S. CBX3/HP1γ promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma. Aging (Albany NY) 2019;11:5483-97. [PMID: 31375643 DOI: 10.18632/aging.102132] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
267 Qiao GJ, Chen L, Wu JC, Li ZR. Identification of an eight-gene signature for survival prediction for patients with hepatocellular carcinoma based on integrated bioinformatics analysis. PeerJ 2019;7:e6548. [PMID: 30918751 DOI: 10.7717/peerj.6548] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
268 Fujiwara N, Kobayashi M, Fobar AJ, Hoshida A, Marquez CA, Koneru B, Panda G, Taguri M, Qian T, Raman I, Li QZ, Hoshida H, Sezaki H, Kumada H, Tateishi R, Yokoo T, Yopp AC, Chung RT, Fuchs BC, Baumert TF, Marrero JA, Parikh ND, Zhu S, Singal AG, Hoshida Y. A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med (N Y) 2021;2:836-850.e10. [PMID: 34318286 DOI: 10.1016/j.medj.2021.03.017] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
269 Sceusi EL, Loose DS, Wray CJ. Clinical implications of DNA methylation in hepatocellular carcinoma. HPB (Oxford). 2011;13:369-376. [PMID: 21609368 DOI: 10.1111/j.1477-2574.2011.00303.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
270 Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F, Alesse E. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013;2013:187204. [PMID: 23533994 DOI: 10.1155/2013/187204] [Cited by in Crossref: 209] [Cited by in F6Publishing: 190] [Article Influence: 23.2] [Reference Citation Analysis]
271 Behnke M, Reimers M, Fisher R. The expression of embryonic liver development genes in hepatitis C induced cirrhosis and hepatocellular carcinoma. Cancers (Basel) 2012;4:945-68. [PMID: 23667740 DOI: 10.3390/cancers4030945] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
272 Hu H, Takano N, Xiang L, Gilkes DM, Luo W, Semenza GL. Hypoxia-inducible factors enhance glutamate signaling in cancer cells. Oncotarget 2014;5:8853-68. [PMID: 25326682 DOI: 10.18632/oncotarget.2593] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
273 Markowitz GJ, Michelotti GA, Diehl AM, Wang XF. Inflammatory models drastically alter tumor growth and the immune microenvironment in hepatocellular carcinoma. Sci Bull (Beijing) 2015;60:762-72. [PMID: 26029472 DOI: 10.1007/s11434-015-0772-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
274 Kwon SM, Lee YK, Min S, Woo HG, Wang HJ, Yoon G. Mitoribosome Defect in Hepatocellular Carcinoma Promotes an Aggressive Phenotype with Suppressed Immune Reaction. iScience 2020;23:101247. [PMID: 32629612 DOI: 10.1016/j.isci.2020.101247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
275 Ji J, Eggert T, Budhu A, Forgues M, Takai A, Dang H, Ye Q, Lee JS, Kim JH, Greten TF, Wang XW. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. Hepatology 2015;62:481-95. [PMID: 25833323 DOI: 10.1002/hep.27822] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 13.2] [Reference Citation Analysis]
276 Affo S, Yu LX, Schwabe RF. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. Annu Rev Pathol 2017;12:153-86. [PMID: 27959632 DOI: 10.1146/annurev-pathol-052016-100322] [Cited by in Crossref: 183] [Cited by in F6Publishing: 173] [Article Influence: 36.6] [Reference Citation Analysis]
277 Lee HA, Lee YS, Kim BK, Jung YK, Kim SU, Park JY, Kim JH, An H, Kim DY, Yim HJ, Ahn SH, Yeon JE, Byun KS, Han KH, Um SH, Seo YS. Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. Gut Liver 2021;15:420-9. [PMID: 32839362 DOI: 10.5009/gnl20101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Ow GS, Tang Z, Kuznetsov VA. Big data and computational biology strategy for personalized prognosis. Oncotarget 2016;7:40200-20. [PMID: 27229533 DOI: 10.18632/oncotarget.9571] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
279 Lai I, Swaminathan S, Baylot V, Mosley A, Dhanasekaran R, Gabay M, Felsher DW. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. J Immunother Cancer 2018;6:125. [PMID: 30458889 DOI: 10.1186/s40425-018-0431-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
280 Choi SM, Kim Y, Liu H, Chaudhari P, Ye Z, Jang YY. Liver engraftment potential of hepatic cells derived from patient-specific induced pluripotent stem cells. Cell Cycle. 2011;10:2423-2427. [PMID: 21750407 DOI: 10.4161/cc.10.15.16869] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
281 Hwang HW, Ha SY, Bang H, Park CK. ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection. Cancer Res Treat 2015;47:853-61. [PMID: 25687855 DOI: 10.4143/crt.2014.177] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
282 Yeung BH, Shek FH, Lee NP, Wong CK. Stanniocalcin-1 Reduces Tumor Size in Human Hepatocellular Carcinoma. PLoS One 2015;10:e0139977. [PMID: 26469082 DOI: 10.1371/journal.pone.0139977] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
283 Cescon M, Bertuzzo VR, Ercolani G, Ravaioli M, Odaldi F, Pinna AD. Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol. 2013;19:9174-9182. [PMID: 24409045 DOI: 10.3748/wjg.v19.i48.9174] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
284 Di Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, Lleo A. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol 2019;25:6041-52. [PMID: 31686761 DOI: 10.3748/wjg.v25.i40.6041] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
285 Wang W, Wang Z, Zhao J, Wei M, Zhu X, He Q, Ling T, Chen X, Cao Z, Zhang Y, Liu L, Shi M. A novel molecular and clinical staging model to predict survival for patients with esophageal squamous cell carcinoma. Oncotarget 2016;7:63526-36. [PMID: 27556859 DOI: 10.18632/oncotarget.11362] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
286 Musella V, Callari M, Di Buduo E, Scuro M, Dugo M, Miodini P, Bianchini G, Paolini B, Gianni L, Daidone MG, Cappelletti V. Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients. PLoS One 2015;10:e0123194. [PMID: 25844937 DOI: 10.1371/journal.pone.0123194] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
287 Hung HH, Su CW, Lai CR, Chau GY, Chan CC, Huang YH, Huo TI, Lee PC, Kao WY, Lee SD. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatol Int. 2010;4:691-699. [PMID: 21286339 DOI: 10.1007/s12072-010-9213-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
288 Singhal G, Kumar G, Chan S, Fisher FM, Ma Y, Vardeh HG, Nasser IA, Flier JS, Maratos-Flier E. Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet. Mol Metab. 2018;13:56-66. [PMID: 29753678 DOI: 10.1016/j.molmet.2018.03.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
289 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. Mol Med Rep 2020;21:1849-60. [PMID: 32319631 DOI: 10.3892/mmr.2020.10991] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
290 Yip SH, Fujiwara N, Burke J, Shetler A, Peralta C, Qian T, Hoshida H, Zhu S, Hoshida Y. MPIC: Molecular Prognostic Indicators in Cirrhosis Database for Clinical Context-Specific in Silico Prognostic Biomarker Validation. Front Genet 2019;10:830. [PMID: 31620162 DOI: 10.3389/fgene.2019.00830] [Reference Citation Analysis]
291 Turato C, Vitale A, Fasolato S, Ruvoletto M, Terrin L, Quarta S, Ramirez Morales R, Biasiolo A, Zanus G, Zali N. SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. Br J Cancer. 2014;110:2708-2715. [PMID: 24809782 DOI: 10.1038/bjc.2014.246] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
292 Castven D, Fischer M, Becker D, Heinrich S, Andersen JB, Strand D, Sprinzl MF, Strand S, Czauderna C, Heilmann-Heimbach S, Roessler S, Weinmann A, Wörns MA, Thorgeirsson SS, Galle PR, Matter MS, Lang H, Marquardt JU. Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas. Oncotarget 2017;8:48688-700. [PMID: 28415775 DOI: 10.18632/oncotarget.16231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
293 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Int J Med Sci 2021;18:2466-79. [PMID: 34104078 DOI: 10.7150/ijms.54239] [Reference Citation Analysis]
294 Govaere O, Petz M, Wouters J, Vandewynckel YP, Scott EJ, Topal B, Nevens F, Verslype C, Anstee QM, Van Vlierberghe H, Mikulits W, Roskams T. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. Oncogene 2017;36:6605-16. [PMID: 28783171 DOI: 10.1038/onc.2017.260] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
295 Zhu HT, Dong QZ, Sheng YY, Wei JW, Wang G, Zhou HJ, Ren N, Jia HL, Ye QH, Qin LX. MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. PLoS One 2012;7:e52393. [PMID: 23285022 DOI: 10.1371/journal.pone.0052393] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
296 Moeini A, Torrecilla S, Tovar V, Montironi C, Andreu-Oller C, Peix J, Higuera M, Pfister D, Ramadori P, Pinyol R, Solé M, Heikenwälder M, Friedman SL, Sia D, Llovet JM. An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. Gastroenterology 2019;157:1383-1397.e11. [PMID: 31344396 DOI: 10.1053/j.gastro.2019.07.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
297 Zhuang PY, Wang JD, Tang ZH, Zhou XP, Quan ZW, Liu YB, Shen J. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma. BMC Cancer. 2015;15:830. [PMID: 26525581 DOI: 10.1186/s12885-015-1763-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
298 Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, Tan TX, Wu MC, Getz G, Lawrence MS. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology. 2013;58:1693-1702. [PMID: 23728943 DOI: 10.1002/hep.26540] [Cited by in Crossref: 191] [Cited by in F6Publishing: 174] [Article Influence: 23.9] [Reference Citation Analysis]
299 Schneider C, Teufel A, Yevsa T, Staib F, Hohmeyer A, Walenda G, Zimmermann HW, Vucur M, Huss S, Gassler N, Wasmuth HE, Lira SA, Zender L, Luedde T, Trautwein C, Tacke F. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut 2012;61:1733-43. [PMID: 22267597 DOI: 10.1136/gutjnl-2011-301116] [Cited by in Crossref: 107] [Cited by in F6Publishing: 102] [Article Influence: 11.9] [Reference Citation Analysis]
300 Ren Z, He S, Fan X, He F, Sang W, Bao Y, Ren W, Zhao J, Ji X, Wen H. Survival prediction model for postoperative hepatocellular carcinoma patients. Medicine (Baltimore) 2017;96:e7902. [PMID: 28906371 DOI: 10.1097/MD.0000000000007902] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
301 Chiu M, Tardito S, Pillozzi S, Arcangeli A, Armento A, Uggeri J, Missale G, Bianchi MG, Barilli A, Dall'Asta V, Campanini N, Silini EM, Fuchs J, Armeanu-Ebinger S, Bussolati O. Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts. Br J Cancer 2014;111:1159-67. [PMID: 25072259 DOI: 10.1038/bjc.2014.425] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
302 Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-233. [PMID: 19167326 DOI: 10.1016/j] [Cited by in F6Publishing: 92] [Reference Citation Analysis]
303 Cao HH, Zhang SY, Shen JH, Wu ZY, Wu JY, Wang SH, Li EM, Xu LY. A three-protein signature and clinical outcome in esophageal squamous cell carcinoma. Oncotarget. 2015;6:5435-5448. [PMID: 25605255 DOI: 10.18632/oncotarget.3102] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
304 Shi JH, Line PD. Effect of liver regeneration on malignant hepatic tumors. World J Gastroenterol. 2014;20:16167-16177. [PMID: 25473170 DOI: 10.3748/wjg.v20.i43.16167] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
305 Wang J, Zhang KY, Liu SM, Sen S. Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules. 2014;19:1912-1938. [PMID: 24518808 DOI: 10.3390/molecules19021912] [Cited by in Crossref: 104] [Cited by in F6Publishing: 97] [Article Influence: 14.9] [Reference Citation Analysis]
306 Ryaboshapkina M, Hammar M. Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis. Sci Rep 2017;7:12361. [PMID: 28955037 DOI: 10.1038/s41598-017-10930-w] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
307 Marongiu F, Serra MP, Sini M, Angius F, Laconi E. Clearance of senescent hepatocytes in a neoplastic-prone microenvironment delays the emergence of hepatocellular carcinoma. Aging (Albany NY) 2014;6:26-34. [PMID: 24464501 DOI: 10.18632/aging.100631] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
308 Jung KS, Kim JH, Kim SU, Song K, Kim BK, Park JY, Kim DY, Ahn SH, Moon DC, Song IJ, Choi GH, Park YN, Han KH. Liver stiffness value-based risk estimation of late recurrence after curative resection of hepatocellular carcinoma: development and validation of a predictive model. PLoS One 2014;9:e99167. [PMID: 24910997 DOI: 10.1371/journal.pone.0099167] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
309 Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51. [PMID: 20175032 DOI: 10.1055/s-0030-1247131] [Cited by in Crossref: 212] [Cited by in F6Publishing: 202] [Article Influence: 19.3] [Reference Citation Analysis]
310 Lupberger J, Croonenborghs T, Roca Suarez AA, Van Renne N, Jühling F, Oudot MA, Virzì A, Bandiera S, Jamey C, Meszaros G, Brumaru D, Mukherji A, Durand SC, Heydmann L, Verrier ER, El Saghire H, Hamdane N, Bartenschlager R, Fereshetian S, Ramberger E, Sinha R, Nabian M, Everaert C, Jovanovic M, Mertins P, Carr SA, Chayama K, Dali-Youcef N, Ricci R, Bardeesy NM, Fujiwara N, Gevaert O, Zeisel MB, Hoshida Y, Pochet N, Baumert TF. Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus-Infected Cells and Liver to Identify Pathways Associated With Disease Development. Gastroenterology 2019;157:537-551.e9. [PMID: 30978357 DOI: 10.1053/j.gastro.2019.04.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
311 Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer. 2015;15:653-667. [PMID: 26493646 DOI: 10.1038/nrc4017] [Cited by in Crossref: 166] [Cited by in F6Publishing: 147] [Article Influence: 33.2] [Reference Citation Analysis]
312 Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61:847-854. [PMID: 22427238 DOI: 10.1136/gutjnl-2011-300865] [Cited by in Crossref: 374] [Cited by in F6Publishing: 356] [Article Influence: 41.6] [Reference Citation Analysis]
313 Boutros PC. The path to routine use of genomic biomarkers in the cancer clinic. Genome Res 2015;25:1508-13. [PMID: 26430161 DOI: 10.1101/gr.191114.115] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
314 Guo Z, Li LQ, Jiang JH, Ou C, Zeng LX, Xiang BD. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. World J Gastroenterol. 2014;20:2098-2106. [PMID: 24616575 DOI: 10.3748/wjg.v20.i8.2098] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 55] [Article Influence: 10.2] [Reference Citation Analysis]
315 Enguita-Germán M, Fortes P. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World J Hepatol. 2014;6:716-737. [PMID: 25349643 DOI: 10.4254/wjh.v6.i10.716] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
316 Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2013;10:34-42. [PMID: 23147664 DOI: 10.1038/nrgastro.2012.199] [Cited by in Crossref: 210] [Cited by in F6Publishing: 199] [Article Influence: 23.3] [Reference Citation Analysis]
317 De Giorgi V, Buonaguro L, Worschech A, Tornesello ML, Izzo F, Marincola FM, Wang E, Buonaguro FM. Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis. PLoS One 2013;8:e56153. [PMID: 23441164 DOI: 10.1371/journal.pone.0056153] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
318 Ouaguia L, Mrizak D, Renaud S, Moralès O, Delhem N. Control of the inflammatory response mechanisms mediated by natural and induced regulatory T-cells in HCV-, HTLV-1-, and EBV-associated cancers. Mediators Inflamm 2014;2014:564296. [PMID: 25525301 DOI: 10.1155/2014/564296] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
319 Fujiwara N, Qian T, Koneru B, Hoshida Y. Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. Hepatol Res 2020;50:817-30. [PMID: 32323426 DOI: 10.1111/hepr.13506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
320 Chou SH, Ko BS, Chiou JS, Hsu YC, Tsai MH, Chiu YC, Yu IS, Lin SW, Hou HA, Kuo YY, Lin HM, Wu MF, Chou WC, Tien HF. A knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironment. PLoS One 2012;7:e49769. [PMID: 23226219 DOI: 10.1371/journal.pone.0049769] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
321 Gravendeel LA, de Rooi JJ, Eilers PH, van den Bent MJ, Sillevis Smitt PA, French PJ. Gene expression profiles of gliomas in formalin-fixed paraffin-embedded material. Br J Cancer 2012;106:538-45. [PMID: 22187034 DOI: 10.1038/bjc.2011.547] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
322 Subramanian H, Roy HK, Pradhan P, Goldberg MJ, Muldoon J, Brand RE, Sturgis C, Hensing T, Ray D, Bogojevic A, Mohammed J, Chang JS, Backman V. Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. Cancer Res 2009;69:5357-63. [PMID: 19549915 DOI: 10.1158/0008-5472.CAN-08-3895] [Cited by in Crossref: 90] [Cited by in F6Publishing: 65] [Article Influence: 7.5] [Reference Citation Analysis]
323 Ton CC, Vartanian N, Chai X, Lin MG, Yuan X, Malone KE, Li CI, Dawson A, Sather C, Delrow J, Hsu L, Porter PL. Gene expression array testing of FFPE archival breast tumor samples: an optimized protocol for WG-DASL sample preparation. Breast Cancer Res Treat 2011;125:879-83. [PMID: 20842525 DOI: 10.1007/s10549-010-1159-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
324 Li W, Yu J, Lian B, Sun H, Li J, Zhang M, Li L, Li Y, Liu Q, Xie L. Identifying prognostic features by bottom-up approach and correlating to drug repositioning. PLoS One 2015;10:e0118672. [PMID: 25738841 DOI: 10.1371/journal.pone.0118672] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
325 Ouyang L, Lee J, Park CK, Mao M, Shi Y, Gong Z, Zheng H, Li Y, Zhao Y, Wang G, Fu H, Kim J, Lim HY. Whole-genome sequencing of matched primary and metastatic hepatocellular carcinomas. BMC Med Genomics 2014;7:2. [PMID: 24405831 DOI: 10.1186/1755-8794-7-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
326 Moeini A, Cornellà H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer. 2012;1:83-93. [PMID: 24159576 DOI: 10.1159/0003424-05] [Reference Citation Analysis]
327 Singal AG, Ioannou GN. For Whom is Hepatocellular Carcinoma Surveillance After Sustained Virologic Response Cost-Effective? Clin Gastroenterol Hepatol 2019;17:1732-5. [PMID: 30772587 DOI: 10.1016/j.cgh.2019.02.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
328 Wooden B, Goossens N, Hoshida Y, Friedman SL. Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology 2017;152:53-67.e3. [PMID: 27773806 DOI: 10.1053/j.gastro.2016.09.065] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
329 Fouad YM, Mostafa I, Yehia R, El-Khayat H. Biomarkers of Barrett’s esophagus. World J Gastrointest Pathophysiol. 2014;5:450-456. [PMID: 25400988 DOI: 10.4291/wjgp.v5.i4.450] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
330 Pelizzaro F, Vitale A, Sartori A, Vieno A, Penzo B, Russo FP, Frigo AC, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Celsa C, Marra F, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Coccoli P, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F, On Behalf Of Ita Li Ca Study Group. Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. Cancers (Basel) 2021;13:897. [PMID: 33672751 DOI: 10.3390/cancers13040897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
331 Iovanna JL, Closa D. Factors released by the tumor far microenvironment are decisive for pancreatic adenocarcinoma development and progression. Oncoimmunology 2017;6:e1358840. [PMID: 29147622 DOI: 10.1080/2162402X.2017.1358840] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
332 Tu T, Budzinska MA, Maczurek AE, Cheng R, Di Bartolomeo A, Warner FJ, McCaughan GW, McLennan SV, Shackel NA. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci. 2014;15:9422-9458. [PMID: 24871369 DOI: 10.3390/ijms15069422] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
333 Khanal T, Choi K, Leung YK, Wang J, Kim D, Janakiram V, Cho SG, Puga A, Ho SM, Kim K. Loss of NR2E3 represses AHR by LSD1 reprogramming, is associated with poor prognosis in liver cancer. Sci Rep 2017;7:10662. [PMID: 28878246 DOI: 10.1038/s41598-017-11106-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
334 Wang XW, Thorgeirsson SS. Transcriptome analysis of liver cancer: ready for the clinic? J Hepatol 2009;50:1062-4. [PMID: 19328580 DOI: 10.1016/j.jhep.2009.02.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
335 Sonnenblick A, Zahavi T. Accelerated carcinogenesis following liver resection in chronically inflamed livers: A window of opportunity for treatment. Biomed Rep 2017;6:545-8. [PMID: 28515912 DOI: 10.3892/br.2017.882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
336 Trépo E, Goossens N, Fujiwara N, Song WM, Colaprico A, Marot A, Spahr L, Demetter P, Sempoux C, Im GY, Saldarriaga J, Gustot T, Devière J, Thung SN, Minsart C, Sersté T, Bontempi G, Abdelrahman K, Henrion J, Degré D, Lucidi V, Rubbia-Brandt L, Nair VD, Moreno C, Deltenre P, Hoshida Y, Franchimont D. Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis. Gastroenterology 2018;154:965-75. [PMID: 29158192 DOI: 10.1053/j.gastro.2017.10.048] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
337 Chen XX, Cheng JW, Huang A, Zhang X, Wang J, Fan J, Zhou J, Yang XR. The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis. Onco Targets Ther 2017;10:5363-75. [PMID: 29180870 DOI: 10.2147/OTT.S150281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
338 Tang CH, Wei W, Liu L. Regulation of DNA repair by S-nitrosylation. Biochim Biophys Acta 2012;1820:730-5. [PMID: 21571039 DOI: 10.1016/j.bbagen.2011.04.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
339 Alvarez MJ, Sumazin P, Rajbhandari P, Califano A. Correlating measurements across samples improves accuracy of large-scale expression profile experiments. Genome Biol 2009;10:R143. [PMID: 20042104 DOI: 10.1186/gb-2009-10-12-r143] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
340 Hou Y, Zou Q, Ge R, Shen F, Wang Y. The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res. 2012;22:259-272. [PMID: 21862973 DOI: 10.1038/cr.2011.139] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 7.6] [Reference Citation Analysis]
341 Colombo F, Baldan F, Mazzucchelli S, Martin-Padura I, Marighetti P, Cattaneo A, Foglieni B, Spreafico M, Guerneri S, Baccarin M. Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma. PLoS One. 2011;6:e21369. [PMID: 21731718 DOI: 10.1371/journal.pone.0021369] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 4.2] [Reference Citation Analysis]
342 Lee B, Ha SY, Song DH, Lee HW, Cho SY, Park CK. High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma. Gut Liver 2014;8:662-8. [PMID: 25368754 DOI: 10.5009/gnl13392] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
343 Gilbert LA, Hemann MT. Chemotherapeutic resistance: surviving stressful situations. Cancer Res 2011;71:5062-6. [PMID: 21771909 DOI: 10.1158/0008-5472.CAN-11-0277] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
344 Maida M, Iavarone M, Raineri M, Cammà C, Cabibbo G. Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. World J Hepatol 2015;7:2053-7. [PMID: 26301047 DOI: 10.4254/wjh.v7.i17.2053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
345 Wang L, Wang J, Zhang X, Li J, Wei X, Cheng J, Ling Q, Xie H, Zhou L, Xu X, Zheng S. Diagnostic Value of Preoperative Needle Biopsy for Tumor Grading Assessment in Hepatocellular Carcinoma. PLoS One. 2015;10:e0144216. [PMID: 26658912 DOI: 10.1371/journal.pone.0144216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
346 Gao Q, Shi Y, Wang X, Zhou J, Qiu S, Fan J. Translational medicine in hepatocellular carcinoma. Front Med. 2012;6:122-133. [PMID: 22573220 DOI: 10.1007/s11684-012-0193-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
347 Phan JH, Moffitt RA, Stokes TH, Liu J, Young AN, Nie S, Wang MD. Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment. Trends Biotechnol 2009;27:350-8. [PMID: 19409634 DOI: 10.1016/j.tibtech.2009.02.010] [Cited by in Crossref: 60] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
348 Ha SY, Kim JH, Yang JW, Kim J, Kim B, Park CK. The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis. Cancer Res Treat 2016;48:1065-73. [PMID: 26511806 DOI: 10.4143/crt.2015.302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
349 Venkatesh A, Sun X, Hoshida Y. Prognostic gene signature profiles of hepatitis C-related early-stage liver cirrhosis. Genom Data 2014;2:361-2. [PMID: 25506552 DOI: 10.1016/j.gdata.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
350 Wang J, Li Y, Ma Q, Huang J. miR‑378 in combination with ultrasonic irradiation and SonoVue microbubbles transfection inhibits hepatoma cell growth. Mol Med Rep 2020;21:2493-501. [PMID: 32236628 DOI: 10.3892/mmr.2020.11045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
351 Lin YR, Yang WJ, Yang GW. Prognostic and immunological potential of PPM1G in hepatocellular carcinoma. Aging (Albany NY) 2021;13:12929-54. [PMID: 33952716 DOI: 10.18632/aging.202964] [Reference Citation Analysis]
352 Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61:847-54. [PMID: 22427238 DOI: 10.1136/gutjnl-2011-300865] [Cited by in Crossref: 100] [Cited by in F6Publishing: 96] [Article Influence: 11.1] [Reference Citation Analysis]
353 Shi J, Keller JM, Zhang J, Keller ET. A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors. J Hepatocell Carcinoma 2014;1:1-7. [PMID: 27508171 DOI: 10.2147/JHC.S44537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
354 Gores GJ. Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib. Nat Rev Gastroenterol Hepatol 2014;11:645-7. [PMID: 25245016 DOI: 10.1038/nrgastro.2014.157] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
355 Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut 2019;68:1065-75. [PMID: 30108162 DOI: 10.1136/gutjnl-2018-316408] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 24.7] [Reference Citation Analysis]
356 Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. Cancers (Basel) 2020;12:E1275. [PMID: 32443546 DOI: 10.3390/cancers12051275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
357 Fuchs BC, Hoshida Y, Fujii T, Wei L, Yamada S, Lauwers GY, McGinn CM, DePeralta DK, Chen X, Kuroda T, Lanuti M, Schmitt AD, Gupta S, Crenshaw A, Onofrio R, Taylor B, Winckler W, Bardeesy N, Caravan P, Golub TR, Tanabe KK. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology. 2014;59:1577-1590. [PMID: 24677197 DOI: 10.1002/hep.26898] [Cited by in Crossref: 195] [Cited by in F6Publishing: 173] [Article Influence: 27.9] [Reference Citation Analysis]
358 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
359 Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov 2017;7:1018-29. [PMID: 28619981 DOI: 10.1158/2159-8290.CD-17-0613] [Cited by in Crossref: 157] [Cited by in F6Publishing: 59] [Article Influence: 39.3] [Reference Citation Analysis]
360 Yu LH, Li N, Cheng SQ. The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. Int J Hepatol. 2011;2011:416459. [PMID: 21994855 DOI: 10.4061/2011/416459] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
361 Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol. 2014;20:10223-10237. [PMID: 25132740 DOI: 10.3748/wjg.v20.i30.10223] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
362 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 593] [Article Influence: 345.0] [Reference Citation Analysis]
363 Kwon Y, Park M, Jang M, Yun S, Kim WK, Kim S, Paik S, Lee HJ, Hong S, Kim TI, Min B, Kim H. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype. Oncotarget 2017;8:39367-81. [PMID: 28455965 DOI: 10.18632/oncotarget.17023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
364 Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, Swanton C, Tomlinson I, Delorenzi M, Fiocca R, Van Cutsem E, Roth A. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist. 2010;15:390-404. [PMID: 20350999 DOI: 10.1634/theoncologist.2009-0233] [Cited by in Crossref: 115] [Cited by in F6Publishing: 99] [Article Influence: 10.5] [Reference Citation Analysis]
365 Wei W, Li B, Hanes MA, Kakar S, Chen X, Liu L. S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. Sci Transl Med 2010;2:19ra13. [PMID: 20371487 DOI: 10.1126/scitranslmed.3000328] [Cited by in Crossref: 78] [Cited by in F6Publishing: 80] [Article Influence: 7.1] [Reference Citation Analysis]
366 Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: Approaching a personalized care. J Hepatol 2015;62:S144-56. [PMID: 25920083 DOI: 10.1016/j.jhep.2015.02.007] [Cited by in Crossref: 136] [Cited by in F6Publishing: 123] [Article Influence: 27.2] [Reference Citation Analysis]
367 Kuo MJ, Mo LR, Chen CL. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods. BMC Cancer 2021;21:250. [PMID: 33685409 DOI: 10.1186/s12885-021-07948-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
368 Huang JC, Basu SK, Zhao X, Chien S, Fang M, Oehler VG, Appelbaum FR, Becker PS. Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration. Blood Cancer J 2015;5:e302. [PMID: 25860293 DOI: 10.1038/bcj.2015.17] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
369 Li B, Feng W, Luo O, Xu T, Cao Y, Wu H, Yu D, Ding Y. Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma. Sci Rep 2017;7:5517. [PMID: 28717245 DOI: 10.1038/s41598-017-04811-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
370 Simon F, Bockhorn M, Praha C, Baba HA, Broelsch CE, Frilling A, Weber F. Deregulation of HIF1-alpha and hypoxia-regulated pathways in hepatocellular carcinoma and corresponding non-malignant liver tissue--influence of a modulated host stroma on the prognosis of HCC. Langenbecks Arch Surg. 2010;395:395-405. [PMID: 20165955 DOI: 10.1007/s00423-009-0590-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
371 Xiang ZL, Zeng ZC, Tang ZY, Fan J, He J, Zeng HY, Zhu XD. Potential prognostic biomarkers for bone metastasis from hepatocellular carcinoma. Oncologist 2011;16:1028-39. [PMID: 21665914 DOI: 10.1634/theoncologist.2010-0358] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
372 Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844-855. [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627] [Cited by in Crossref: 790] [Cited by in F6Publishing: 754] [Article Influence: 112.9] [Reference Citation Analysis]
373 Carr BI, Guerra V. Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase. Oncology. 2013;85:153-159. [PMID: 23988857 DOI: 10.1159/000354416] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
374 Prasad GA, Bansal A, Sharma P, Wang KK. Predictors of progression in Barrett’s esophagus: current knowledge and future directions. Am J Gastroenterol. 2010;105:1490-1502. [PMID: 20104216 DOI: 10.1038/ajg.2010.2] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 7.4] [Reference Citation Analysis]
375 Jeong WK, Jamshidi N, Felker ER, Raman SS, Lu DS. Radiomics and radiogenomics of primary liver cancers. Clin Mol Hepatol 2019;25:21-9. [PMID: 30441889 DOI: 10.3350/cmh.2018.1007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
376 Hoshida Y, Villanueva A, Llovet JM. Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol 2009;3:101-3. [PMID: 19351279 DOI: 10.1586/egh.09.5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
377 Liao R, Fu YP, Wang T, Deng ZG, Li DW, Fan J, Zhou J, Feng GS, Qiu SJ, Du CY. Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China. Oncotarget 2017;8:1774-87. [PMID: 27662665 DOI: 10.18632/oncotarget.12152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
378 Liao W, Liu W, Liu X, Yuan Q, Ou Y, Qi Y, Huang W, Wang Y, Huang J. Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma. Oncotarget 2015;6:24132-47. [PMID: 26125229 DOI: 10.18632/oncotarget.4432] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
379 Zhong C, Wu JD, Fang MM, Pu LY. Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis. Tumour Biol 2015;36:7623-30. [PMID: 25921286 DOI: 10.1007/s13277-015-3487-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
380 Greten TF, Duffy AG, Korangy F. Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res. 2013;19:6678-6685. [PMID: 24030702 DOI: 10.1158/1078-0432.ccr-13-1721] [Cited by in Crossref: 65] [Cited by in F6Publishing: 40] [Article Influence: 8.1] [Reference Citation Analysis]
381 Simon EP, Freije CA, Farber BA, Lalazar G, Darcy DG, Honeyman JN, Chiaroni-Clarke R, Dill BD, Molina H, Bhanot UK, La Quaglia MP, Rosenberg BR, Simon SM. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci U S A 2015;112:E5916-25. [PMID: 26489647 DOI: 10.1073/pnas.1424894112] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 10.5] [Reference Citation Analysis]
382 Schwabe RF, Wang TC. Targeting liver cancer: first steps toward a miRacle? Cancer Cell 2011;20:698-9. [PMID: 22172719 DOI: 10.1016/j.ccr.2011.11.021] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
383 Liu TC, Vachharajani N, Chapman WC, Brunt EM. SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases. Am J Surg Pathol 2014;38:966-72. [PMID: 24805857 DOI: 10.1097/PAS.0000000000000218] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 3.9] [Reference Citation Analysis]
384 Ha SY, Song DH, Lee JJ, Lee HW, Cho SY, Park CK. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma. Gut Liver 2014;8:648-54. [PMID: 25287169 DOI: 10.5009/gnl13406] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
385 Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LL, Susani M, Rioux-Leclercq N, Spratt DE, Morgan TM, Davenport MS, Chinnaiyan AM, Cyrta J, Rubin MA, Shariat SF, Tomlins SA, Palapattu GS. Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 2018;3:123468. [PMID: 30385730 DOI: 10.1172/jci.insight.123468] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
386 Ha SY, Yeo SY, Lee KW, Kim SH. Validation of ORAOV1 as a new treatment target in hepatocellular carcinoma. J Cancer Res Clin Oncol 2021;147:423-33. [PMID: 33161447 DOI: 10.1007/s00432-020-03437-x] [Reference Citation Analysis]
387 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 62] [Article Influence: 96.0] [Reference Citation Analysis]
388 Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori M. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol. 2010;45:146-152. [PMID: 19997856 DOI: 10.1007/s00535-009-0164-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
389 Merle P, Trepo C. Molecular mechanisms underlying hepatocellular carcinoma. Viruses. 2009;1:852-872. [PMID: 21994573 DOI: 10.3390/v1030852] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
390 Takagi K, Takayama T, Nagase H, Moriguchi M, Wang X, Hirayanagi K, Suzuki T, Hasegawa H, Ochiai T, Yamaguchi N, Kochi M, Kimura M, Esumi M. High TSC22D3 and low GBP1 expression in the liver is a risk factor for early recurrence of hepatocellular carcinoma. Exp Ther Med 2011;2:425-31. [PMID: 22977521 DOI: 10.3892/etm.2011.236] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
391 Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 2014;342:223-230. [PMID: 22306342 DOI: 10.1016/j.canlet.2012.01.038] [Cited by in Crossref: 109] [Cited by in F6Publishing: 104] [Article Influence: 12.1] [Reference Citation Analysis]
392 Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011;141:476-85, 485.e1-11. [PMID: 21684283 DOI: 10.1053/j.gastro.2011.04.042] [Cited by in Crossref: 209] [Cited by in F6Publishing: 188] [Article Influence: 20.9] [Reference Citation Analysis]
393 Ganne-Carrié N, Nault JC, Ziol M, N'Kontchou G, Nahon P, Grando V, Bourcier V, Barge S, Beaugrand M, Trinchet JC, Seror O. Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma. Hepat Oncol 2014;1:395-408. [PMID: 30190975 DOI: 10.2217/hep.14.22] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
394 Sheng T, Wang B, Wang SY, Deng B, Qu L, Qi XS, Wang XL, Deng GL, Sun X. The Relationship Between Serum Interleukin-6 and the Recurrence of Hepatitis B Virus Related Hepatocellular Carcinoma after Curative Resection. Medicine (Baltimore). 2015;94:e941. [PMID: 26091457 DOI: 10.1097/MD.0000000000000941] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
395 Bergthold G, Bandopadhayay P, Hoshida Y, Ramkissoon S, Ramkissoon L, Rich B, Maire CL, Paolella BR, Schumacher SE, Tabak B, Ferrer-Luna R, Ozek M, Sav A, Santagata S, Wen PY, Goumnerova LC, Ligon AH, Stiles C, Segal R, Golub T, Grill J, Ligon KL, Chan JA, Kieran MW, Beroukhim R. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol 2015;17:1486-96. [PMID: 25825052 DOI: 10.1093/neuonc/nov045] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
396 von Felden J, Heim D, Schulze K, Krech T, Ewald F, Nashan B, Lohse AW, Wege H. High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. BMC Cancer 2017;17:60. [PMID: 28100188 DOI: 10.1186/s12885-017-3053-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
397 Wang R, Jiao Y, Li Y, Ye S, Pan G, Qin S, Hua F, Liu Y. The Prediction and Prognostic Significance of INPP5K Expression in Patients with Liver Cancer. Biomed Res Int 2020;2020:9519235. [PMID: 32420386 DOI: 10.1155/2020/9519235] [Reference Citation Analysis]
398 Wang L, Huang J, Jiang M, Lin H, Qi L, Diao H. Activated PTHLH coupling feedback phosphoinositide to G-protein receptor signal-induced cell adhesion network in human hepatocellular carcinoma by systems-theoretic analysis. ScientificWorldJournal 2012;2012:428979. [PMID: 22997493 DOI: 10.1100/2012/428979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
399 Braconi C, Valeri N, Kogure T, Gasparini P, Huang N, Nuovo GJ, Terracciano L, Croce CM, Patel T. Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci USA. 2011;108:786-791. [PMID: 21187392 DOI: 10.1073/pnas.1011098108] [Cited by in Crossref: 149] [Cited by in F6Publishing: 141] [Article Influence: 13.5] [Reference Citation Analysis]
400 Hu ZQ, Zhou ZJ, Luo CB, Xin HY, Li J, Yu SY, Zhou SL. Peritumoral plasmacytoid dendritic cells predict a poor prognosis for intrahepatic cholangiocarcinoma after curative resection. Cancer Cell Int 2020;20:582. [PMID: 33292317 DOI: 10.1186/s12935-020-01676-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
401 Deltenre P, Trépo E, Fujiwara N, Goossens N, Marot A, Dubois M, Spahr L, Henrion J, Moreno C, Hoshida Y. Gene signature-MELD score and alcohol relapse determine long-term prognosis of patients with severe alcoholic hepatitis. Liver Int 2020;40:565-70. [PMID: 31568650 DOI: 10.1111/liv.14265] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
402 Cai J, Li B, Zhu Y, Fang X, Zhu M, Wang M, Liu S, Jiang X, Zheng J, Zhang X, Chen P. Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties. EBioMedicine 2017;19:18-30. [PMID: 28434945 DOI: 10.1016/j.ebiom.2017.04.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
403 Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol 2013;35:111-20. [DOI: 10.1007/s00281-012-0330-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
404 Polyak SJ, Crispe IN, Baumert TF. Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure. Pathogens 2021;10:44. [PMID: 33430338 DOI: 10.3390/pathogens10010044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
405 Hsiao YW, Chiu LT, Chen CH, Shih WL, Lu TP. Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas. Genes (Basel) 2019;10:E630. [PMID: 31434354 DOI: 10.3390/genes10080630] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
406 Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S, Calza S, Flavin R, Freedman ML, Setlur S, Sesso HD, Andersson SO, Martin N, Kantoff PW, Johansson JE, Adami HO, Rubin MA, Loda M, Golub TR, Andrén O, Stampfer MJ, Mucci LA. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 2011;29:2391-6. [PMID: 21537050 DOI: 10.1200/JCO.2010.32.6421] [Cited by in Crossref: 105] [Cited by in F6Publishing: 61] [Article Influence: 10.5] [Reference Citation Analysis]
407 Wang X, He B, Gao Y, Li Y. FOXR2 contributes to cell proliferation and malignancy in human hepatocellular carcinoma. Tumour Biol 2016;37:10459-67. [PMID: 26846213 DOI: 10.1007/s13277-016-4923-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
408 Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol. 2013;19:8822-8830. [PMID: 24379605 DOI: 10.3748/wjg.v19.i47.8822] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
409 Ai J, Tang Q, Wu Y, Xu Y, Feng T, Zhou R, Chen Y, Gao X, Zhu Q, Yue X, Pan Q, Xu S, Li J, Huang M, Daugherty-Holtrop J, He Y, Xu HE, Fan J, Ding J, Geng M. The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma. J Natl Cancer Inst 2011;103:1696-712. [PMID: 22025622 DOI: 10.1093/jnci/djr360] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
410 Chen X, Wu F, Liu Y, Lou J, Zhu B, Zou L, Chen W, Gong J, Wang Y, Zhong R. The contribution of serum hepatitis B virus load in the carcinogenesis and prognosis of hepatocellular carcinoma: evidence from two meta-analyses. Oncotarget 2016;7:49299-309. [PMID: 27384478 DOI: 10.18632/oncotarget.10335] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
411 Markowitz GJ, Yang P, Fu J, Michelotti GA, Chen R, Sui J, Yang B, Qin WH, Zhang Z, Wang FS, Diehl AM, Li QJ, Wang H, Wang XF. Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor-Infiltrating Lymphocytes. Cancer Res 2016;76:2394-405. [PMID: 26893476 DOI: 10.1158/0008-5472.CAN-15-1548] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
412 Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut. 2015;64:842-848. [PMID: 25666193 DOI: 10.1136/gutjnl-2014-307990] [Cited by in Crossref: 97] [Cited by in F6Publishing: 98] [Article Influence: 16.2] [Reference Citation Analysis]
413 Saran U, Guarino M, Rodríguez S, Simillion C, Montani M, Foti M, Humar B, St-Pierre MV, Dufour JF. Anti-tumoral effects of exercise on hepatocellular carcinoma growth. Hepatol Commun 2018;2:607-20. [PMID: 29761175 DOI: 10.1002/hep4.1159] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
414 Li Q, Yu CH, Yu JH, Liu L, Xie SS, Li WW, Yang X, Fan WB, Gai ZT, Chen SJ. ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B. PLoS One. 2012;7:e29928. [PMID: 22235351 DOI: 10.1371/journal.pone.0029928] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
415 King LY, Johnson KB, Zheng H, Wei L, Gudewicz T, Hoshida Y, Corey KE, Ajayi T, Ufere N, Baumert TF, Chan AT, Tanabe KK, Fuchs BC, Chung RT. Host genetics predict clinical deterioration in HCV-related cirrhosis. PLoS One 2014;9:e114747. [PMID: 25504078 DOI: 10.1371/journal.pone.0114747] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
416 Rohr-Udilova N, Klinglmüller F, Seif M, Hayden H, Bilban M, Pinter M, Stolze K, Sieghart W, Peck-Radosavljevic M, Trauner M. Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. Oncotarget 2017;8:57109-20. [PMID: 28915658 DOI: 10.18632/oncotarget.19055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
417 Lesluyes T, Delespaul L, Coindre JM, Chibon F. The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms. Sci Rep 2017;7:5480. [PMID: 28710396 DOI: 10.1038/s41598-017-05726-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
418 Qi L, Wang L, Huang J, Jiang M, Diao H, Zhou H, Li X, Jiang Z. Activated amelogenin Y-linked (AMELY) regulation and angiogenesis in human hepatocellular carcinoma by biocomputation. Oncol Lett 2013;5:1075-9. [PMID: 23426651 DOI: 10.3892/ol.2013.1122] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
419 Sadanandam A, Futakuchi M, Lyssiotis CA, Gibb WJ, Singh RK. A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling. BMC Cancer 2011;11:304. [PMID: 21774828 DOI: 10.1186/1471-2407-11-304] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
420 Thompson AI, Conroy KP, Henderson NC. Hepatic stellate cells: central modulators of hepatic carcinogenesis. BMC Gastroenterol. 2015;15:63. [PMID: 26013123 DOI: 10.1186/s12876-015-0291-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 9.7] [Reference Citation Analysis]
421 Fan DM, Wang XJ, He T, Wang Y, Zhou D, Kong GQ, Jiang T, Zhang MM. High expression of TGF-β1 in the vaginal incisional margin predicts poor prognosis in patients with stage Ib-IIa cervical squamous cell carcinoma. Mol Biol Rep 2012;39:3925-31. [PMID: 21773949 DOI: 10.1007/s11033-011-1171-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
422 Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault JC, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Llovet JM, Villanueva A. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology 2021;160:2572-84. [PMID: 33705745 DOI: 10.1053/j.gastro.2021.01.233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
423 King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan PS, Sun X. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut. 2015;64:1296-1302. [PMID: 25143343 DOI: 10.1136/gutjnl-2014-307862] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
424 Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol. 2010;3:55-66. [PMID: 21180590 DOI: 10.1177/1756283x09346669] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
425 Zhang W, Chen J, Liu L, Wang L, Liu J, Su D. Prognostic value of preoperative computed tomography in HBV-related hepatocellular carcinoma patients after curative resection. Onco Targets Ther 2019;12:3791-804. [PMID: 31190879 DOI: 10.2147/OTT.S199136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
426 Pancoska P, Lu SN, Carr BI. Phenotypic Categorization and Profiles of Small and Large Hepatocellular Carcinomas. J Gastrointest Dig Syst 2013;Suppl 12:001. [PMID: 23956952 DOI: 10.4172/2161-069X.S12-001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
427 Hu S, Yuan H, Li Z, Zhang J, Wu J, Chen Y, Shi Q, Ren W, Shao N, Ying X. Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis. Oncotarget 2017;8:41334-47. [PMID: 28489584 DOI: 10.18632/oncotarget.17295] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
428 Carone C, Olivani A, Dalla Valle R, Manuguerra R, Silini EM, Trenti T, Missale G, Cariani E. Immune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor Recurrence. Liver Cancer. 2018;7:277-294. [PMID: 30319985 DOI: 10.1159/000486764] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
429 Chen X, Sun X, Hoshida Y. Survival analysis tools in genomics research. Hum Genomics 2014;8:21. [PMID: 25421963 DOI: 10.1186/s40246-014-0021-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
430 Yu KH, Ricigliano M, McCarthy B, Chou JF, Capanu M, Cooper B, Bartlett A, Covington C, Lowery MA, O'Reilly EM. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E467. [PMID: 30477242 DOI: 10.3390/cancers10120467] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
431 Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. Genes Dis 2020;7:359-69. [PMID: 32884990 DOI: 10.1016/j.gendis.2020.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
432 Ju MJ, Qiu SJ, Fan J, Zhou J, Gao Q, Cai MY, Li YW, Tang ZY. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009;44:635-642. [PMID: 19387533 DOI: 10.1007/s00535-009-0050-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
433 Zhuang L, Zeng X, Yang Z, Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e61361. [PMID: 24069133 DOI: 10.1371/journal.pone.0061361] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
434 Liu C, Sun L, Xu J, Zhao Y. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma. World J Surg Oncol. 2016;14:100. [PMID: 27038790 DOI: 10.1186/s12957-016-0855-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
435 Zhang JB, Guo K, Sun HC, Zhu XD, Zhang B, Lin ZH, Zhang BH, Liu YK, Ren ZG, Fan J. Prognostic value of peritumoral heat-shock factor-1 in patients receiving resection of hepatocellular carcinoma. Br J Cancer 2013;109:1648-56. [PMID: 24002609 DOI: 10.1038/bjc.2013.488] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
436 Wang W, Xu L, Liu P, Jairam K, Yin Y, Chen K, Sprengers D, Peppelenbosch MP, Pan Q, Smits R. Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell Lines Mostly Independent of β-Catenin Signaling. Neoplasia 2016;18:711-23. [PMID: 27851986 DOI: 10.1016/j.neo.2016.10.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
437 Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010;138:958-968. [PMID: 19914252 DOI: 10.1053/j.gastro.2009.11.005] [Cited by in Crossref: 391] [Cited by in F6Publishing: 358] [Article Influence: 32.6] [Reference Citation Analysis]
438 Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, Jeong W, Lee SS, Park ES, Kaseb A. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med. 2014;11:e1001770. [PMID: 25536056 DOI: 10.1371/journal.pmed.1001770] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
439 Villanueva A, Savic R, Llovet JM. Lymphotoxins: new targets for hepatocellular carcinoma. Cancer Cell 2009;16:272-3. [PMID: 19800570 DOI: 10.1016/j.ccr.2009.09.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
440 Gilbert LA, Hemann MT. Context-specific roles for paracrine IL-6 in lymphomagenesis. Genes Dev 2012;26:1758-68. [PMID: 22855834 DOI: 10.1101/gad.197590.112] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
441 Tanabe KK, Hoshida Y. Prognostic gene signatures for hepatocellular carcinoma: what are we measuring? Ann Surg Oncol 2013;20:3707-8. [PMID: 23797752 DOI: 10.1245/s10434-013-3071-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
442 Veenstra C, Karlsson E, Mirwani SM, Nordenskjöld B, Fornander T, Pérez-Tenorio G, Stål O. The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype. J Cancer Res Clin Oncol 2019;145:1845-56. [PMID: 31025094 DOI: 10.1007/s00432-019-02918-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
443 Sherman M. How to improve HCC surveillance outcomes. JHEP Rep 2019;1:460-7. [PMID: 32039398 DOI: 10.1016/j.jhepr.2019.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
444 Kettner NM, Voicu H, Finegold MJ, Coarfa C, Sreekumar A, Putluri N, Katchy CA, Lee C, Moore DD, Fu L. Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis. Cancer Cell 2016;30:909-24. [PMID: 27889186 DOI: 10.1016/j.ccell.2016.10.007] [Cited by in Crossref: 190] [Cited by in F6Publishing: 155] [Article Influence: 38.0] [Reference Citation Analysis]
445 Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014;107:23-30. [PMID: 24726738 DOI: 10.1016/j.antiviral.2014.03.012] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 11.7] [Reference Citation Analysis]
446 Wu J, Du J, Liu L, Li Q, Rong W, Wang L, Wang Y, Zang M, Wu Z, Zhang Y. Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. PLoS One. 2012;7:e50035. [PMID: 23227158 DOI: 10.1371/journal.pone.0050035] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
447 Huang K, Liao X, Han C, Wang X, Yu T, Yang C, Liu X, Yu L, Chen Z, Qin W, Zhu G, Su H, Liu Z, Zeng X, Zhou X, Lu S, Huang J, Liang Y, Liu Z, Deng J, Ye X, Peng T. Genetic variants and Expression of Cytochrome p450 Oxidoreductase Predict Postoperative Survival in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. J Cancer 2019;10:1453-65. [PMID: 31031855 DOI: 10.7150/jca.28919] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
448 Hyeon J, Ahn S, Park CK. CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection. Korean J Pathol. 2013;47:9-15. [PMID: 23482400 DOI: 10.4132/KoreanJPathol. 2013.47.1.9] [Reference Citation Analysis]
449 Zhao X, Luo J, Li B, Liu S, Li D. The association between preoperative serum C-reactive protein and hepatocellular carcinoma recurrence in patients with chronic hepatitis B virus (HBV) infection--a retrospective study. PLoS One. 2015;10:e0116909. [PMID: 25602444 DOI: 10.1371/journal.pone.0116909] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
450 Yang L, Wang X, Xu J, Wen Y, Zhang M, Lu J, Wang R, Sun X. Integrated transcriptomic and proteomic analyses reveal ɑ-lipoic acid-regulated cell proliferation via Grb2-mediated signalling in hepatic cancer cells. J Cell Mol Med 2018;22:2981-92. [PMID: 29575431 DOI: 10.1111/jcmm.13447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
451 Matter MS, Marquardt JU, Andersen JB, Quintavalle C, Korokhov N, Stauffer JK, Kaji K, Decaens T, Quagliata L, Elloumi F, Hoang T, Molinolo A, Conner EA, Weber A, Heikenwalder M, Factor VM, Thorgeirsson SS. Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype. Hepatology 2016;63:1888-99. [PMID: 26844528 DOI: 10.1002/hep.28487] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
452 Staten NR, Welsh EA, Sidik K, McDonald SA, Dufield DR, Maqsodi B, Ma Y, McMaster GK, Mathews RW, Arch RH, Masferrer JL, Souberbielle BE. Multiplex transcriptional analysis of paraffin-embedded liver needle biopsy from patients with liver fibrosis. Fibrogenesis Tissue Repair 2012;5:21. [PMID: 23270325 DOI: 10.1186/1755-1536-5-21] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
453 Aster J, Kutok J. Complexity made simple in diffuse large B-cell lymphoma. Clin Cancer Res 2009;15:5291-3. [PMID: 19706818 DOI: 10.1158/1078-0432.CCR-09-1444] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
454 Izumi D, Gao F, Toden S, Sonohara F, Kanda M, Ishimoto T, Kodera Y, Wang X, Baba H, Goel A. A genomewide transcriptomic approach identifies a novel gene expression signature for the detection of lymph node metastasis in patients with early stage gastric cancer. EBioMedicine 2019;41:268-75. [PMID: 30772302 DOI: 10.1016/j.ebiom.2019.01.057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
455 Archer KJ, Reese SE. Detection call algorithms for high-throughput gene expression microarray data. Brief Bioinform 2010;11:244-52. [PMID: 19939941 DOI: 10.1093/bib/bbp055] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
456 Kakodkar R, Soin AS. Liver Transplantation for HCC: A Review. Indian J Surg. 2012;74:100-117. [PMID: 23372314 DOI: 10.1007/s12262-011-0387-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
457 Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep 2017;16:64-71. [PMID: 28337405 DOI: 10.1007/s11901-017-0336-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
458 Wang L, Yue Y, Wang X, Jin H. Function and clinical potential of microRNAs in hepatocellular carcinoma. Oncol Lett. 2015;10:3345-3353. [PMID: 26788134 DOI: 10.3892/ol.2015.3759] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
459 Kubota N, Fujiwara N, Hoshida Y. Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. J Clin Med 2020;9:E3843. [PMID: 33256232 DOI: 10.3390/jcm9123843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
460 Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight 2020;5:140134. [PMID: 32701508 DOI: 10.1172/jci.insight.140134] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
461 Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013;144:1024-30. [PMID: 23333348 DOI: 10.1053/j.gastro.2013.01.021] [Cited by in Crossref: 125] [Cited by in F6Publishing: 115] [Article Influence: 15.6] [Reference Citation Analysis]
462 Abdueva D, Wing M, Schaub B, Triche T, Davicioni E. Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays. J Mol Diagn 2010;12:409-17. [PMID: 20522636 DOI: 10.2353/jmoldx.2010.090155] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 5.8] [Reference Citation Analysis]
463 Erdem-Eraslan L, Gravendeel LA, de Rooi J, Eilers PH, Idbaih A, Spliet WG, den Dunnen WF, Teepen JL, Wesseling P, Sillevis Smitt PA, Kros JM, Gorlia T, van den Bent MJ, French PJ. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. J Clin Oncol 2013;31:328-36. [PMID: 23269986 DOI: 10.1200/JCO.2012.44.1444] [Cited by in Crossref: 72] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
464 Melis M, Diaz G, Kleiner DE, Zamboni F, Kabat J, Lai J, Mogavero G, Tice A, Engle RE, Becker S, Brown CR, Hanson JC, Rodriguez-Canales J, Emmert-Buck M, Govindarajan S, Kew M, Farci P. Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus-associated hepatocellular carcinoma. J Transl Med 2014;12:230. [PMID: 25141867 DOI: 10.1186/s12967-014-0230-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
465 Umezaki N, Nakagawa S, Yamashita YI, Kitano Y, Arima K, Miyata T, Hiyoshi Y, Okabe H, Nitta H, Hayashi H, Imai K, Chikamoto A, Baba H. Lysyl oxidase induces epithelial-mesenchymal transition and predicts intrahepatic metastasis of hepatocellular carcinoma. Cancer Sci 2019;110:2033-43. [PMID: 30919528 DOI: 10.1111/cas.14010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
466 Zhang T, Guo J, Gu J, Chen K, Wang Z, Li H, Wang G, Wang J. KIAA0101 is a novel transcriptional target of FoxM1 and is involved in the regulation of hepatocellular carcinoma microvascular invasion by regulating epithelial-mesenchymal transition. J Cancer 2019;10:3501-16. [PMID: 31293655 DOI: 10.7150/jca.29490] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
467 Inokawa Y, Inaoka K, Sonohara F, Hayashi M, Kanda M, Nomoto S. Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncol Lett 2016;12:3662-8. [PMID: 27900050 DOI: 10.3892/ol.2016.5141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
468 Moeini A, Cornellà H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer 2012;1:83-93. [PMID: 24159576 DOI: 10.1159/000342405] [Cited by in Crossref: 111] [Cited by in F6Publishing: 103] [Article Influence: 15.9] [Reference Citation Analysis]
469 Woo HG, Choi JH, Yoon S, Jee BA, Cho EJ, Lee JH, Yu SJ, Yoon JH, Yi NJ, Lee KW, Suh KS, Kim YJ. Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer. Nat Commun 2017;8:839. [PMID: 29018224 DOI: 10.1038/s41467-017-00991-w] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 14.5] [Reference Citation Analysis]
470 Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M, Mazzaferro V. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology 2013;57:1426-35. [PMID: 22576353 DOI: 10.1002/hep.25832] [Cited by in Crossref: 189] [Cited by in F6Publishing: 166] [Article Influence: 23.6] [Reference Citation Analysis]
471 Yang S, Yan HL, Tao QF, Yuan SX, Tang GN, Yang Y, Wang LL, Zhang YL, Sun SH, Zhou WP. Low CADM2 expression predicts high recurrence risk of hepatocellular carcinoma patients after hepatectomy. J Cancer Res Clin Oncol. 2014;140:109-116. [PMID: 24240726 DOI: 10.1007/s00432-013-1536-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
472 Plaz Torres MC, Lai Q, Piscaglia F, Caturelli E, Cabibbo G, Biasini E, Pelizzaro F, Marra F, Trevisani F, Giannini EG. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. J Clin Med 2021;10:3201. [PMID: 34361985 DOI: 10.3390/jcm10153201] [Reference Citation Analysis]
473 Goto K, Roca Suarez AA, Wrensch F, Baumert TF, Lupberger J. Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. Int J Mol Sci. 2020;21. [PMID: 32357520 DOI: 10.3390/ijms21093057] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]